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1 Abstract
Vaccination has the power to eradicate viral diseases and is a promising approach to cure
cancer. However, modern vaccination strategies repeatedly fail in inducing a robust cy-
totoxic CD8+ T cell response, which is needed to eradicate virus-infected or malignantly
transformed cells. One way to improve this induction is the targeting of C-type lectin
receptors on dendritic cells (DCs) that lead to the presentation of antigens on MHC
class I molecules to CD8+ T cells in a process termed cross-presentation. In addition,
certain C-type lectin receptors have the capacity to induce DC maturation, which pro-
vides the second crucial signal to induce cytotoxic T cell activation. Yeasts such as
Pichia pastoris produce N-glycans that are able to ligate such C-type lectin receptors
and are thus generally considered to be immunostimulatory. N-glycosylation by P. pas-
toris might hence be exploited in vaccine strategies to promote both MHC I-restricted
antigen presentation and DC maturation. However, the benefit of such a vaccination
approach remains elusive since the particular effect of P. pastoris-derived N-glycans on
a cellular and humoral response in vivo has not been investigated so far.
Here we tested whether it is possible to introduce N-glycans on proteins that are not
glycosylated in their native state by recombinant expression in P. pastoris in order to
target C-type lectin receptors and increase antigen cross-presentation. For this pur-
pose we expressed β-galactosidase (β-gal), a cytosolic Escherichia coli protein bearing
several potential glycosylation sites, and a GFP-derivative with an engineered glyco-
sylation site (NST-GFP) in P. pastoris. We show that both intrinsic and artificially
designed N-glycosylation motifs are readily glycosylated after secretion by P. pastoris.
We demonstrate that the attached N-glycans ligate the calcium-dependet carbohydrate
recognition domains of the mannose receptor (MR), a C-type lectin receptor that me-
diates cross-presentation of the model antigen ovalbumin (OVA). Antigens internalized
by bone marrow-derived dendritic cells (BM-DCs) were consistently routed to OVA-
positive compartments related to cross-presentation. However, subsequent in vitro anal-
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ysis revealed that P. pastoris-derived N-glycans had no immunostimulatory capacity on
BM-DCs per se. To elucidate the impact of such enforced N-glycosylation in vivo we sub-
cutaneously immunized mice with N-glycosylated or enzymatically deglycosylated β-gal
or NST-GFP. Surprisingly, the effect of N-glycosylation on in vivo cross-presentation
proved to be dependent on the nature of the antigen. The presence of N-glycans in-
creased the in vivo cytotoxicity against β-gal, whereas a decrease was observed against
NST-GFP fused to an immunodominant OVA-epitope. Importantly, for both antigens
tested we observed a reduction of the humoral immune response in the presence of N-
glycans as indicated by decreased serum IgG in comparison to the group immunized
with deglycosylated proteins.
Our data demonstrate that P. pastoris can be used to tag non-glycoproteins with
N-glycans that target the MR. However, a beneficial effect of such N-glycans on in
vivo cross-presentation was dependent on the antigen, and the presence of N-glycans
consistently decreased a humoral response. These findings have important implications
on recombinant vaccines using Pichia pastoris as an expression system.
2
2 Introduction
2.1 Human health and the co-evolution of vaccination
and immunology
Infectious diseases were the main causatives of death worldwide until the beginning of the
20th century, and are still important contributors to morbidity and mortality today [1–3].
With the introduction of vaccination once common infectious diseases such as measles
or diphtheria were nearly eradicated in industrialized regions like North America, thus
leading to a strong decrease in child-mortality in these regions and demonstrating the
potential of vaccination to contribute to human health [3–5].
The development of vaccination is profoundly linked to the emergence of immunology
as a natural science. Since the proof by Edward Jenner in 1798 that infection with
cow-pox induces immunity against small-pox [6], vaccination strategies continuously co-
evolved with both the knowledge of the immune system and the technological advances
in natural sciences [7]. The introduction of genetic engineering or the identification of
pattern recognition receptors as modulators of the immune system are only two examples
that have promoted the development of vaccines to become more effective, to have less
side-effects, and to cover more diseases [7].
From a historical point of view, vaccination was developed to fight infectious (i.e.
communicable) diseases. Yet, in recent years, vaccination strategies have also been
translated to non-communicable diseases (NCDs) e.g. cancer, Alzheimer’s desease or
autoimmune and chronic inflammatory diseases such as diabetes [8–10]. In any case, ever
since then the idea of vaccination has been to activate the host’s own immune system
by a harmless vaccine, to eventually fight harmful threats like pathogens and ideally
to develop an immunological memory that conveys long-lasting immunity against that
certain threat.
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Despite the progress in vaccine formulation and immunological research, vaccination
design remains challenging as effective vaccines for major health risks like the human
immunodeficiency virus (HIV), tuberculosis or malaria are still lacking [11, 12]. One
major task for effective vaccination design is the consistent and strong activation of
both arms of the so-called adaptive immune response [11, 13].
2.2 The basics of our immune system
The immune system can be divided into two interconnected parts, the innate and the
adaptive immune system (Figure 2.1) [14]. The innate immune system is a general term
for our body’s first line of defense mechanisms against pathogens. These include physical
barriers like epithelial surfaces, several cellular components, for example phagocytic cells
like macrophages (MΦs) or dendritic cells (DCs), and mechanisms based on a protein
network known as the complement system. In terms of first-line-defense, the innate
immune system relies on the recognition of conserved pathogen-associated molecular
patterns (PAMPs) to quickly restrict the spread of pathogens and simultaneously acti-
vate the more specific adaptive immune system [15, 16]. Vaccination strategies mainly
aim at the activation of the adaptive immune system with its inherent property to detect
virtually any possible antigen.
Innate  immunity
innate  first  line  of  defense
pathogen-­unspecific
relies  on  PAMPs
no  memory
Adaptive  immunity
develops  after  contact  with  pathogen  
pathogen-­specific
relies  on  gene-­rearrangement  and  clonal  expansion
immunological  memory
Cellular  response Humoral  response
-­  CD8+  cytotoxic  T  cells
-­  CD4+  T  helper  cells
-­  antibody-­producing  
B  cells
-­  physical  barriers
-­  complement  system
-­  cellular  components,  e.g.
     macrophages
     dendritic  cells
The  immune  system
} APCs
Figure 2.1: The immune system
The scheme gives a condensed overview of the components and their properties
that constitute the immune system as described in the text.
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The two pillars of the adaptive immune system are a humoral and a cellular immune
response. The humoral response comprises the generation of antigen specific antibodies
by specialized B lymphocytes [17, 18], whereas the cellular response consists of the
activation of antigen specific T lymphocytes which are able to carry out diverse cellular
functions [19–22]. A rough discrimination of certain effector T cell phenotypes is possible
by their characteristic cluster of differentiation (CD) surface molecules. Effector T cells
which are able to kill other cells and are hence called cytotoxic T lymphocytes (CTLs) are
positive for CD8 [20]. Effector T cells which act as T helper cells (Th cells), e.g. in helping
B cells to mount an efficient humoral immune response, are positive for CD4 [23]. The
key step of T cell activation (T cell priming) is mediated by so-called professional antigen
presenting cells (APCs) from the innate immune system, which are mainly dendritic cells
and macrophages.
In the case of viral infections, it becomes particularly obvious why it is so important
for modern vaccines to activate both arms of the adaptive immune response. A humoral
response will be able to neutralize free virus particles and maybe cells from which viral
particles are actively budding. But many viruses, e.g. HIV or the hepatitis B virus
(HBV), can hide within cells, thereby forming a resting reservoir that will lead to viral
rebound if the infected cell is not eliminated directly [24, 25]. Hence, full eradication of
a virus will be most likely if both the humoral and the cellular cytotoxic response are
activated.
2.3 Antigen presentation links innate immunity to the
adaptive immune response
The key to understanding how antigens evoke either humoral or cytotoxic responses lies
within the process of antigen presentation and T cell priming by professional antigen
presenting cells such as dendritic cells.
2.3.1 Dendritic cells sense danger signals and are capable of
antigen presentation and T cell priming
Dendritic cells are a heterogenous group of cells specialized in antigen presentation [26,
27]. Peripheral dendritic cells screen the tissues for PAMPs and take up extracellular
5
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material by macropinocytosis and receptor-mediated endocytosis to eventually present
antigen-derived peptides on major histocompatibility complex (MHC) molecules to T
cells. Detection of PAMPs is carried out by a heterogenous group of germ-line encoded
receptors, named pattern recognition receptors (PRRs) [28]. PRRs comprise secreted,
membrane-bound and intracellular receptors of diverse receptor classes that engage in
multiple functions like complement activation, phagocytosis and DC activation. Due to
their important role in innate immune cell activation, PRRs like the toll-like receptor
(TLR) family became important targets not only for fine-tuning vaccines to elicit appro-
priate immune responses against the different types of pathogens [29] but also to inhibit
unwanted inflammation [30].
The first human TLR to be characterized was TLR4 [31]. A well-known ligand of
this type-1 membrane protein is lipopolysaccharide (LPS), a main cell wall component
of gram-negative bacteria [32]. Signaling via TLR4 triggers diverse dose-dependent
pathways in DCs that can lead to the increased surface expression of co-stimulatory
molecules like CD40, CD80 and CD86, the migration towards lymph nodes and the
release of cytokines [33–36]. These phenotypic changes are collectively known as DC
maturation [37]. Once in the lymph node, they encounter circulating na¨ıve T cells,
which screen the incoming DCs with their unique T cell receptor (TCR) for their cognate
antigen. DCs express MHC class I and II, which specifically interact with the TCRs
of CD8+ and CD4+ T lymphocyte, respectively. However, a proper T cell activation
requires more than a mere interaction of the MHC-peptide complex with the TCR. The
second essential step is the activation of CD28-signaling in the T cell, which is mediated
by the above-mentioned co-stimulatory molecules CD80 and CD86 on the DC. This is
one of the key checkpoints in T cell activation as it guarantees tolerance to peptides in
the absence of a danger signal (such as TLR-agonists). Upon activation, T cells start
to proliferate and differentiate into CTLs in the case of CD8+ or into T helper cells (Th
cells) in the case of CD4+ T lymphocytes (Figure 2.2). Proliferation is accompanied by
interleukin-2 (IL-2) secretion and autocrine self-stimulation by the IL-2 receptor on T
cells [38], which can be exploited to measure T cell proliferation in vitro.
After TLR-activation, DCs and Macrophages also secrete inflammatory cytokines such
as interleukin-6 (IL-6), interleukin-12 (IL-12) or tumor necrosis factor alpha (TNF-α).
IL-6 and TNF-α are mainly known as mediators of the classical inflammation symptoms
(e.g. fever) and the induction of acute phase proteins of the innate immune system [39,
40]. Besides their effects on innate immunity, cytokines further refine the appropriate
6
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DC
Th
CTL
IL-­2
IL-­2
T  cell
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MHC  I MHC  II CD4 CD8 antigen-­derived
peptides
CD28 CD80/
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Th
Th Th
CTL
CTL CTL
CD8+
CD4+
Figure 2.2: T cell priming by dendritic cells requires antigen presentation on MHC
molecules and co-stimulation
A dendritic cell (DC) presents antigen-derived peptides to na¨ıve CD4+ and CD8+
T lymphocytes via MHC class II and class I molecules, respectively. In addition
to the interaction between the T cell receptor and the MHC-peptide complex,
T cell activation requires co-stimulation of CD28 via CD80/CD86 expressed by
the dendritic cell. T cell proliferation is further induced and sustained by au-
tocrine IL-2 signaling. CD4+ T cells differentiate into Th cells, CD8+ T cells into
cytotoxic T lymphocytes (CTL).
cellular program of adaptive effector cells. IL-12 for example promotes CD4+ Th cell
differentiation into a subset called Th1 cells, which produce Interferon gamma (IFN-γ)
and support macrophage activation and CTL generation [41].
2.3.2 Cytotoxic T cells
The CD8+ cytotoxic T lymphocyte is the major cellular effector cell of the adaptive
immune response when it comes to the eradication of malignant or pathogen-infected
cells. Hence, the induction of CTLs is a central goal in vaccination strategies. In contrast
to MHC class II expression, which is restricted to professional APCs, MHC class I is
expressed by all nucleated cells. Upon activation by DCs, CTLs are attracted to the
sites of inflammation where they screen target cells for the presentation of their cognate
7
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MHC-I-peptide complex. After recognition, the CTL can engage several mechanism for
their cytotoxic activity. These include the secretion of cytokines like TNF or IFN-γ, the
induction of apopotosis through cell-contact mediated death receptor (FAS) activation
on the target cell and the release of cytotoxic granules, which rely on the cytolytic
activity of granzymes and perforin [20].
2.3.3 The role of MHC II-restricted presentation to CD4+ T helper
cells in B cell activation
The key player in the humoral response is the B lymphocyte. Like T cells, they express
a unique receptor that is a product of gene-rearrangement [42]. This B cell receptor
(BCR) is part of the immunoglobulin superfamily and represents the membrane-bound
variant of the antibody, which can be secreted by the B cell after appropriate activation.
In contrast to the MHC-restricted T cell receptor, the BCR directly binds native and
unprocessed antigens. But similar to T cells, proper B cell activation requires more
than one signal. The first signal comes from BCR cross-linking after antigen binding.
For most protein antigens the second signal, however, is delivered by CD4+ Th cell-
activity [23]. Like macrophages and DCs, B cells express MHC II molecules which are
loaded with antigen-derived peptides [43]. These MHC II-peptide complexes are then
recognized by antigen-experienced (i.e. previously activated) CD4+ Th cells that in
turn deliver the second signal for B cell activation by cytokines release (e.g. IL-4) and
membrane-bound activators like CD40L that binds to CD40 on the B-cell [23]. B cells
can additionally undergo several rounds of somatic hypermutation of their BCR, followed
by Th cell-dependent selection and expansion of only those clones that express a BCR
with increased affinity [44]. After this affinity maturation, B cells finally differentiate into
antibody secreting plasma or memory B cells [44, 45]. Moreover, class switching from
immunoglobulins (Ig) IgM and IgD to IgG, IgA and IgE takes place [46], of which IgG
is the most abundant antibody found in the plasma [47]. Class switching also depends
on CD4+ Th cells and is modulated by cytokines [46]. Hence, a strong humoral response
with high affinity antibodies requires Th cell activity, and this in turn requires preceding
MHC II-restricted presentation from APCs like DCs to na¨ıve CD4+ T cells.
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2.3.4 Antigen uptake and processing by dendritic cells dictates
MHC restriction and forms the basis of rational vaccine
design to specifically elicit cytotoxic activity
As described above, the activation of CD8+ CTLs requires antigen presentation in the
MHC class I context, whereas a potent humoral response to protein antigens requires
CD4+ Th cell activity, and hence MHC class II-restricted presentation. In DCs, the
loading of MHC class II molecules with antigen-derived peptides occurs in late endo-
somes/lysosomes. The source of such antigens comprises extracellular antigens that are
taken up by the cell and enter the endo/lysosomal pathway of degradation but might
also include intracellular antigens, which enter lysosomes by autophagy [37]. The com-
mon MHC class I loading machinery is situated within the endoplasmic reticulum (ER)
and is supplied by cytosolic proteins that were cleaved into peptides by the proteasome
[48]. However, if self-synthesized cytosolic proteins were the only source of MHC class
I loading, the immune system would not be able to present viral antigens from viruses
that do not infect DCs, and tumor-derived antigens would never be presented to cy-
totoxic T lymphocytes except if a DC itself turned malignant. Fortunately, dendritic
cells have developed an additional mechanism that allows the presentation of extracel-
lular antigens on MHC class I molecules — a process termed cross-presentation [49,
50]. The determination whether an extracellular antigen is presented on MHC class II
molecules or cross-presented on MHC class I molecules was shown to depend on the
uptake mechanism (Figure 2.3) [51]. It could be demonstrated that the model antigen
ovalbumin (OVA) enters the classical endolysosmal/MHC class II pathway if it is taken
up by macropinocytosis or scavenger receptor (SR)-mediated endocytosis, whereas it is
cross-presented after internalization by the mannose receptor (MR). It turned out that
the MR shuttles OVA to a distinct compartment which is positive for early endosomal
markers like the early endosome antigen-1 (EEA1) and transferrin (Trf), but negative for
the lysosomal marker lysosomal-associated membrane protein 1 (LAMP-1) [51]. From
here the antigen is exported into the cytosol, degraded by the proteasome, re-imported
into the same compartment and loaded in situ onto MHC class I molecules by an MHC
class I loading machinery spatially separated from the ER [52].
The MR is only one of several PRRs on DCs that supply the cross-presentation path-
way with internalized antigens [53–60].
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Coupling antigens to natural ligands or antibodies against these receptors is a promis-
ing approach to increase uptake and subsequent MHC I-restricted presentation by DCs
in order to induce a cytotoxic T cell response in vaccination strategies.
CD
4+
T  c
ell
CD8+
T  cell
Lysosomes
LAMP-­1+
Early  
endosomes
MR+
EEA1+
Trf+
Pinocytosis
MR-­mediated
endocytosis
SR-­mediated
endocytosis
DC
MHC  II-­restricted  
presentation
MHC  I-­restricted
cross-­presentation
ProteasomeOvalbumin Transporter MHC  I
OVA-­derived
peptideMannose  receptor TAP MHC  II
Lysosomal
proteasesScavenger  receptor
T  cell
receptor
Figure 2.3: Distinct pathways direct exogenous antigens towards MHC I- or MHC
II-restricted presentation
Ovalbumin that is taken up by scavenger receptor (SR)-mediated endocytosis or
pinocytosis is directed towards lysosomal degradation and MHC class II-restricted
presentation to CD4+ T cells. If ovalbumin is endocytosed by the mannose re-
ceptor (MR), it enters a distinct early endosomal compartment from where it
is processed for MHC class I-restricted cross-presentation to CD8+ T cells. DC
= dendritic cell, LAMP-1 = lysosomal-associated membrane protein 1, EEA1 =
early endosome antigen-1, Trf = transferrin, TAP = transporter associated with
antigen processing. The graphic is based on Burgdorf et al. 2007 and Kreer et
al. 2012 [50, 51].
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2.4 The macrophage mannose receptor (MR, CD206)
The mannose receptor is a multidomain type I membrane protein and belongs to the C-
type lectin-like receptors. C-type lectins are a huge family of proteins [61] that have one
or several conserved carbohydrate recognition domains (CRDs). CRDs bind carbohy-
drates in a calcium-dependent manner [62] and are also referred to as C-type lectin-like
domains (CTLDs) [63]. The MR consists of an N-terminal cysteine-rich (CR) domain
and a fibronectin II (FNII) domain, which are followed by 8 CRDs, a transmembrane
domain and a short cytoplasmic tail (Figure 2.4). The CR domain binds to sulfated car-
bohydrates (SO4-(3)-galactose and SO4-(3/4)-N-Acetylgalactosamine) [64, 65], whereas
the FNII domain binds to collagen (I, II, III, IV and to a much lesser degree to V)
[66, 67]. The C-type lectin activity is mediated by the CRDs 4–8, whereas CRDs 1–
3 do not bear carbohydrate-binding properties [68]. From the CRDs 4–8, only CRD4
shows strong binding to the monosaccharides mannose, fucose and N-Acetylglucosamine
in isolation [68]. High affinity binding to multivalent ligands, however, requires the par-
ticipation of the CRDs 4–7 [69]. Binding studies with isolated human MR revealed a
prevalence of branched over linear mannose oligosaccharides or monosaccharides [70].
Two well-described ligands of the MR are yeast mannan and the model antigen ovalbu-
min (OVA). Mannan is a natural polymer derived from Saccharomyces cerevisiae and
consists of multiple α-1,2-, α-1,3- or α-1,6-linked mannose residues [71]. OVA, a ∼45 kDa
glycoprotein with high-mannose glycans attached to Asn292 [72], is the main component
of hen egg white.
Upon antigen internalization, the MR enters early endosomes from where it recycles
back to the cell surface [73, 74]. In the steady state, roughly 80% of the MR are present
within these recycling endosomes [75]. The short cytoplasmic N-terminal tail harbors a
di-aromatic motif (Tyr18-Phe19), which was reported to be essential for receptor inter-
nalization and sorting in recycling endosomes [76]. The MR lacks further signaling motifs
in its cytoplasmic tail and concordantly did not induce cytokine release upon binding
to mannan [77]. In the same study, however, cross-linking ligands like antibodies or
mannose-capped lipoarabinomannan (ManLAM) induced anti-inflammatory cytokines
[77]. In contrast, other studies reported the MR-dependent release of pro-inflammatory
cytokines [78, 79]. The data are discussed controversially, and Gazi et al. suggested
that the MR engages signaling-competent co-receptors which account for the diverse
signaling pathways but is not able to signal on its own as shown for mannan [80].
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Figure 2.4: The mannose receptor
The MR comprises different types of protein domains that differ in their ligand
specificities. GlcNAc = N-Acetylglucosamine. This modified graphic is based on
Martinez-Pomares et al. 2006 [66].
The MR is expressed by subsets of several myeloid immune cells including mono-
cytes, macrophages, dendritic cells or Langerhans cells, but also by endothelial cells
like the dermal microvascular endothelial cells (DMECs) and liver sinusoidal endothe-
lial cells (LSECs) [81, 82]. Specifically in monocytes, macrophages and dendritic cells,
MR expression and engagement for antigen uptake seem to be tightly controlled by the
activation state and show variations depending on whether cells were freshly isolated or
generated in vitro [81, 83–85]. Besides its participation in antigen uptake it also plays a
crucial role in collagen internalization by macrophages [86] and LSECs [87]. Addition-
ally, the MR has been reported to regulate serum glycoprotein homeostasis [88] and to
mediate cell adhesion and trafficking, for example by its expression on lymphatic vessels
[89].
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2.5 Information encoded by glycans
The natural ligands of C-type lectins like the MR are polysaccharides. One type of
polysaccharides — called glycans — can be attached to other macromolecules, such as
lipids (e.g. in the case of LPS) or proteins. The most important building blocks for
protein associated glycans are the carbohydrates summed up in Table 2.1.
Table 2.1: Monosaccharide building blocks of glycans
Galactose
Glucose
Mannose
N-­Acetylgalactosamine
N-­Acetylglucosamine
Fucose
N-­Acetylneuraminic  
          acid  (Sialic  acid)
Xylose
Name AbbreviationSymbol
Gal
Glc
Man
GalNAc
GlcNAc
Fuc
NANA
Xyl
Glycosylation (i.e. the attachment of glycans) is a major post-translational modifica-
tion on proteins in eukaryotic cells. Two types of glycosylations, N- and O-glycosylation,
are distinguished due to their linkage to the protein and their side of synthesis [90]. N-
glycosylation starts co-translationally in the endoplasmic reticulum. During protein syn-
thesis, the N-glycosylation motif N-X-S/T (where X denotes any amino acid except pro-
line) is recognized by a glycosyltransferase that transfers a pre-assembled high-mannose
core-glycan to the amide nitrogen of the asparagine within that motif [91]. Core glycans
can be further edited during the secretory pathway in the ER and the Golgi apparatus
[92]. This occurs by several glycosidases and glycosyltransferases, which trim or add spe-
cific monosaccharides ending up in three major types of glycans in animal cells, namely
high-mannose, complex or hybrid type (Figure 2.5). In contrast, O-glycosylation takes
strictly place post-translationally in the Golgi apparatus by the linkage of a monosaccha-
ride to the hydroxyle group of either serine or threonine [93] (Figure 2.5). In mammals,
the first monosaccharide is typically a GalNAc, which is subsequently branched by Gal
or GlcNAc at C3, and potentially by another GlcNAc at C6 to form several types of core
structures. The core is then elongated by sequential addition of further monosaccharides.
Up to date, there is no consensus sequence known for O-glycosylation, thus making this
type of modification hardly predictable. Convenient tools for glycan analysis are spe-
cific glycosidases like Endoglycosidase H (Endo H), which cleaves between the first two
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N-X-S/T N-X-S/T N-X-S/T
High-mannose Hybrid Complex
S/T
N-linked glycans O-linked glycans
Gal
GlcNAc
NANA
Man
GalNAc
Endo H
PNGase F
Figure 2.5: Glycans in mammalian cells
N-linked glycans are attached to the nitrogen of an asparagine in the N-X-S/T
motif and can be separated into the three groups depicted above. O-linked glycans
consist of one out of four possible core structures attached to the side-chain of
either serine or threonine, which is then further elongated. All glycans depict
representative examples and may vary in the total number and, except for high-
mannose, in the types of the attached monosaccharides. Dashed lines indicate
cleavage sites of the glycosidases Endo H and PNGase F. The O-linked glycan
depicts a core 2 structure. N = asparagine, X = any amino acid except proline,
S = serine, T = threonine.
GlcNAc within high-mannose and some hybrid N-glycans or Peptide-N-Glycosidase F
(PNGase F), which cleaves between the first GlcNAc and asparagine (Figure 2.5).
Glycans play diverse roles in vivo, ranging from the rendering of protein-properties
like solubility and stability to cell-adhesion and communication [94]. In terms of commu-
nication, glycans are able to decode high levels of information through their structural
properties. In contrast to amino acids, which always form a backbone through the amine
and carboxylic acid at the alpha carbon, monosaccharides can engage all of their free hy-
droxyle groups to form glycosidic bonds at several positions. The result is the formation
of branched glycans which have a complex three-dimensional structure. This directly
reflects in the variety and substrate specificity of C-type lectins like the MR. Several
C-type lectins might have conserved CRDs that show the same affinity for a monosac-
charide like mannose. However, keeping in mind that most lectins engage several CRDs
to yield high affinity binding, they can still differ in their natural glycan ligand due to
the three-dimensional orientation of their CRDs [95].
It seems obvious that eukaryotic glycans differ from prokaryotic glycans, as the latter
lack the ER and Golgi apparatus. But also eukaryotic glycans greatly differ from each
other, as glycosylation pathways have evolved differently during eukaryotic evolution
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[96]. Yeasts have only a limited set of additional glycosyltransferases resulting in the
formation of high-mannose glycans only [71]. Yet, differences in glycans also occur be-
tween different yeast-genera such as Saccharomyces cerevisiae and Pichia pastoris by the
favored engagement of certain linkages, branching and the number of monosaccharides
added to the core structure [97]. Plants can add α-1,3-linked fucose and the pentose
xylose to their glycan core, which are both not present in mammalian glycans and hence
immunogenic [98]. Mammalian glycans, on the other hand, are often capped by sialic
acid (N-Acetylneuraminic acid) [90]. Even within the same species unique glycans de-
fine subgroups of individuals, as impressively demonstrated by the human blood groups,
which have strong clinical relevance in the case of transfusion and transplantation [99].
Given this high content of information encoded by glycans, it is not surprising that
the mammalian immune system makes use of them to detect pathogens and discriminate
non-self from self or harmful from harmless. Immunologists realized the role of non-self
glycans as targets of the immune system early, and in the late 70s of the 20th century
the first polysaccharide based vaccine was published, which was derived by purification
from meningococci [100, 101].
2.6 The advent of defined vaccine formulations and the
challenges for modern vaccines
The earliest vaccines followed the principle of attenuation, where live, attenuated patho-
gens were administered to convey immunity against a severe pathogen [7]. The prototype
attenuated vaccine by Edward Jenner was a pathogen-related virus that is less harmful
[6]. Later, attenuation was achieved by cell culture methods yielding mutated viruses
that had lost their virulency, yet kept their immunogenicity [102, 103]. Another approach
that was quickly translated into vaccination was the killing or inactivation of pathogenic
bacteria and viruses [104]. Both approaches have their drawbacks. The first includes
mainly the risk of unintentional regain of the pathogen’s virulency after administration
[105]. The second approach, though safer in general, often shows reduced immunogenic-
ity, thus leading to the requirement of additional adjuvants [106]. Both have in common
that they are highly empirical approaches. Though the genome of a pathogen might
be fully sequenced these days, the precise amount of each of the thousands of different
macromolecule and their individual and composite influence on the immune-response
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are hardly predictable. Hence, the trend has shifted towards defined vaccine formula-
tions that contain subunits of the pathogens as antigens [3, 105, 107] . Historically, this
strategy started with the purification of pathogen-derived macromolecules such as the
polysaccharides of meningococci [100]. In terms of pathogen-derived proteins, this ap-
proach was then strongly promoted by the advent of recombinant protein technologies.
Nowadays, potential subunit vaccines are produced in the whole spectrum of available
prokaryotic and eukaryotic expression systems [7, 105, 108].
Sole administration of proteinaceous subunit vaccines, however, is often ineffective in
eliciting CD8+ T cell responses and will, if at all, primarily induce humoral immunity
[105]. This is likely to be attributed to several factors. First, to be efficiently presented
to T cells, antigens have to be taken up by DCs and processed towards MHC class
I- or class II-restricted presentation. Depending on the vaccine administration route,
however, unspecific pinocytosis by DCs might compete with other cells that contribute
to in vivo clearance. Furthermore, the uptake of antigens by pinocytosis favors MHC
II-restricted presentation [51], thereby skewing the immune response towards humoral
immunity. Second, proteinaceous vaccines without any PAMP are not able to induce
DC maturation and will rather induce tolerance than immunity [53]. Therefore, current
subunit vaccines have to be supplied with adjuvants to activate TLRs or other receptors
that induce DC maturation [53, 109, 110].
Taken together these weak points illustrate the strong need for strategies that on the
one hand specifically target receptors on DCs that mediate cross-presentation and on
the other hand simultaneously activate the DCs to eventually induce a strong CD8+ T
cell response.
2.7 Pichia pastoris and its usage in vaccine development
Yeast expression systems combine the advantages of prokaryotic expression systems like
the simple and cost-efficient high yield production of recombinant proteins with the
potential to add eukaryotic post-translational modifications. Among all possible yeasts,
Pichia pastoris (P. pastoris) has recently gained increasing popularity in the production
of recombinant subunit vaccines [108]. P. pastoris was introduced as an expression
system in 1985 [111]. This yeast strain is special in that it can grow on methanol as
the sole carbon source. Commercial expression vectors like the pPICZ vectors (Life
Technologies, Thermo Fisher Scientific) make use of the methanol induced alcohol oxi-
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dase 1 promotor to drive strong protein expression which is precisely controllable [112].
The yeast is capable of growing at high cell densities, thus allowing the production
of large biomass cultures, which results in high protein yields (up to 14.8 g/L have
been reported [113]). Accordingly, several studies have used P. pastoris to yield high
amounts of recombinant subunit vaccines [114–116]. Like other yeasts, P. pastoris is
only capable of adding high-mannose glycans to its glycoproteins. In comparison to S.
cerevisiae it tends less to hypermannosylation, which is the repetitive addition of an α-
1,6-linked mannose moiety to one antennary that can be elongated with further mannose-
residues in α-1,2-linkages [117]. Due to their potential recognition by C-type lectin
receptors of the immune system, yeast-derived high-mannose glycans have repeatedly
been considered to be immunogenic [112, 117, 118], and a lot of effort has been put in
the humanization of glycosylation pathways, especially in terms of human therapeutic
proteins [119]. On the other hand, an intrinsic adjuvancy and the potential to target
C-type lectin receptors related to cross-presentation represent two valuable properties
for subunit vaccines as described above. Accordingly, glycoproteins like ovalbumin [120]
or the P-selectin glycoprotein ligand-1 [121] were intentionally expressed in P. pastoris
with the goal to increase their immunogenicity, and in vitro studies prove that such
glycoproteins are indeed recognized by C-type lectins including the MR and dendritic
cell-specific ICAM-3 grabbing non-integrin (DC-SIGN) [122, 123]. This suggests that
the addition of yeast-derived glycans to any protein could be used as a strategy to
target C-type lectin receptors for improved cross-presentation and eventually eliciting a
cytotoxic T cell response in vivo. Such an approach would be especially valuable if it
could be translated to subunit vaccines that are not glycosylated in their native state. N-
glycosylation by P. pastoris is initiated by the N-X-S/T amino acid sequon that could be
exploited as a glycosylation tag for such subunit vaccines. However, the precise impact
of P. pastoris-derived N-glycans on the in vivo response remains unclear, as none of
the available studies directly compared N-glycosylated versus deglycosylated proteins
in vivo. Furthermore, the concept that yeast-derived mannosylation per se increases
immunogenicity remains controversial, as mannose-specific receptors like the MR were
also reported to act in homeostasis [124], and MR-targeting on monocyte-derived DCs
even led to the secretion of anti-inflammatory cytokines [77].
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2.8 Aims of this thesis
A potent cytotoxic T cell response is a prerequisite for an efficient anti-viral or anti-tumor
immune response and remains a challenging task in today’s vaccine design. C-type lectin
receptors like the MR are involved in antigen cross-presentation and are hence promis-
ing targets for vaccines that aim at evoking such cytotoxic responses. Glycoproteins
expressed in P. pastoris have been shown to bind C-type lectin receptors including the
MR, thus demonstrating that glycosylation by P. pastoris is a potential targeting strat-
egy for the MR.
The primary goal of the present work was to investigate whether N-glycosylation by
P. pastoris is a convenient way to target C-type lectins like the MR in order to improve
cross-presentation in vaccination strategies. In this respect it was of particular interest to
develop a strategy to N-glycosylate proteins that lack glycans in their native state. The
binding of such proteins to MR subdomains and the uptake and subcellular localization
in DCs were to be carefully characterized, since cross-presentation of OVA requires the C-
type lectin activity of the MR and its subsequent localization in distinct early endosomal
compartments. Finally, the applicability of the developed targeting strategy for vaccine
design was to be critically evaluated. Therefore, the immunostimulatory capacity of
the P. pastoris-derived N-glycans and their impact on the cellular and humoral immune
response were to be determined.
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3.1 Materials
3.1.1 Electronic devices
Device Name Manufacturer Category Specifications
5417R Eppendorf Centrifuge F45-30-11 rotor
5810R Eppendorf Centrifuge A-4-81 rotor
Allegra X-15R Beckmann Coulter Centrifuge SX4730 rotor
ARE VELP Scientifica Heating magnetic
stirrer
Multi-purpose stirrer
Avanti J-26XP Beckmann Coulter Centrifuge JA-14, JA-25.50,
JLA-8.100 rotor
BioLogic LP Bio-Rad low-pressure
chromatography
system
LP chromatography,
operated with Model
2110 fraction collector
CB 210 Binder CO2 Incubator Cell culture
ChemiDoc MP Bio-Rad Imaging system Gel and WB detection
FluoroMax-4
Spectroflurometer
Horiba Fluorescence
spectrometer
Fluorescence
spectroscopy
FiveEasy Mettler Toledo pH Meter Operated with LE409
glasselectrode
Gauva easyCate Merck Millipore Flow cytometer Flow cytometry
Infinite R© 200 PRO Tecan Multimode plate
reader
Fluorescence
measurement 96-well
format, ELISA
Innova 40 and 44 New Brunswick Incubator shaker Bacteria/Yeast
incubation
Continued on next page
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Device Name Manufacturer Category Specifications
LSR II BD Bioscience Flow cytometer Partially operated
with HTS system,
flow cytometry
Mini-PROTEAN Tetra
Cell
Bio-Rad Vertical
electrophoresis
system
SDS-PAGE
Mini-Sub Cell GT Cell
and Wide Mini-Sub
Cell GT Cell
Bio-Rad Horizontal
gelelectrophoresis
system
DNA-gel
electrophoresis
Multiskan Plus Type
355
Thermo Scientific Microplate Reader ELISA
NanoDrop 2000 Thermo Scientific Spectrophotometer UV-Vis spectroscopy
NanoVue Plus GE Healthcare Spectrophotometer OD measurement
PowerPac Basic and
PowerPac HC
Bio-Rad Power Supply Power supply for
Bio-Rad
electrophoresis and
Trans-Blot cells
Sonopuls HD 2070 Bandelin Sonicator Operated with MS 37
sonotrode
Trans-Blot SD Bio-Rad Semi-Dry Transfer
Cell
Semi-Dry WB
Universal Oven UN-55 Memmert Incubator Bacteria/Yeast
incubation
Vortex mixer ZX3 VELP Scientifica Vortex mixer Sample mixing
3.1.2 Consumables
Consumable* Manufacturer
24-well plate, tissue culture treated (PS) TPP
48-well plate, tissue culture treated (PS) TPP
96-well plate, tissue culture treated (PS) TPP
96-well plate, round bottom (PS) Sarstedt
96-well Microlon ELISA plate, flat bottom, high binding (PS) Greiner
96-well FLUOTRAC plate, black, flat bottom, high binding (PS) Greiner
Continued on next page
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Consumable* Manufacturer
Amersham Protran 0.2 NC western blotting membrane (0.2 µm pore size,
nitrocellulose)
GE Healthcare
Amicon Ultra-4 and -15 centrifugal filter untis (10, 30 and 50 kDa
MWCO)
Merck Millipore
BD Plastipak Syringe (1, 10 and 5 mL, PP/PS/rubber) BD
Erlenmyer flasks, baffled (5 L, borosilicate glass 3.3) Labomedic
Beaker (0.1−1 liter, borosilicate glass 3.3) Duran
Blotting paper (1.5 mm) Carl Roth
Bottle-top 1 L vacuum filters (0.22 µm pore size, CA) Corning
Conical tubes (15 and 50 mL, PP) Sarstedt
Econo-Column Chromatography Column (1.5×75 cm, glass) Bio-Rad
Electroporation cuvettes (0.2 cm, PC) Bio-Rad
Laboratory bottle (0.1−2 L, borosilicate glass 3.3) Duran
Measuring cylinder (0.5 , 1 L borosilicate glass 3.3) Duran
PCR tubes (0.2 mL, PP) Bio-Rad
Petri dishes (92×16 mm, PS) Sarstedt
Reaction tubes (0.5, 1.5 and 2 mL, PP) Sarstedt
Serological pipettes (5, 10 and 25 mL, PS) Sarstedt
Syringe filter, sterile (0.2 µm, CA/PVDF) VWR
Tissue culture flask T75, Standard with ventilation cap (75 cm2, PS) Sarstedt
Tissue culture dish, Standard (10×2 mm and 15×2 mm, PS) Sarstedt
Vivaflow 200 crossflow casette (30 kDa MWCO, Hydrosart) Sartorius
*CA - cellulose acetate, PC - polycarbonate, PP - polypropylene, PS - polystyrene, PVDF -
polyvinylidene fluoride
3.1.3 Antibodies
Antibody Species Clone or
Cat. No.
Vendor Conju-
gate
Stock Applica-
tion*
Anti-EEA1
(H-300)
Rabbit sc-33585 Santa Cruz - 0.2 mg/mL IF
Anti-FLAG Rabbit F7425 Sigma-
Aldrich
- 0.8 mg/mL ELISA,
WB
Anti-His Mouse AD1.1.10 AbD Serotec - 1 mg/mL ELISA,
WB
Continued on next page
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Antibody Species Clone or
Cat. No.
Vendor Conju-
gate
Stock Applica-
tion*
Anti-Human
CD206 (MMR)
Mouse 15-2 BioLegend Biotin 0.5 mg/mL FC
Anti-Human IgG Rabbit sc-2769 Santa Cruz HRP 0.4 mg/mL ELISA,
WB
Anti-Human IgG
AP
Goat sc-2454 Santa Cruz AP 0.4 mg/mL ELISA
Anti-Mouse CD4 Rat GK1.5 BioLegend PerCP/
Cy5.5
0.2 mg/mL FC
Anti-Mouse
CD8α
Rat 53-6.7 eBioscience PerCP/
Cy5.5
0.2 mg/mL FC
Anti-Mouse
CD40
Rat 1C10 eBioscience PE 1 mg/mL FC
Anti-Mouse
CD80 (B7-1)
Armenian
Ham-
ster
16-10A1 eBioscience PE 0.5 mg/mL FC
Anti-Mouse
CD86
Rat PO3 AbD Serotec Alexa
Fluor
488
0.05 mg/mL FC
Anti-Mouse
CD107a
(LAMP-1)
Rat 1D4B
(RUO)
BD
Biosciences
- 0.5 mg/mL IF
Anti-Mouse
CD206
Rat MR5D3 AbD Serotec Alexa
Fluor
488
0.05 mg/mL IF
Anti-Mouse IgG Goat sc-2005 Santa Cruz HRP 0.4 mg/mL ELISA,
WB
Anti-Mouse IL-2 Rat JES6-
1A12
eBioscience - 0.5 mg/mL ELISA
(Capture)
Anti-Mouse IL-2
Biotin
Rat JES6-5H4 eBioscience Biotin 0.5 mg/mL ELISA
(Detection)
Anti-Mouse IL-6 Rat MP5-
20F3
eBioscience - 0.5 mg/mL ELISA
(Capture)
Anti-Mouse IL-6
Biotin
Rat MP5-
32C11
eBioscience Biotin 0.5 mg/mL ELISA
(Detection)
Anti-Mouse
IL-12p40
Rat C15.6 eBioscience - 0.5 mg/mL ELISA
(Capture)
Anti-Mouse
IL-12p40 Biotin
Rat C17.8 eBioscience Biotin 0.5 mg/mL ELISA
(Detection)
Anti-Mouse
IFN-γ
Rat AN-18 eBioscience - 0.5 mg/mL ELISA
(Capture)
Anti-Mouse
IFN-γ Biotin
Rat R496A2 eBioscience Biotin 0.5 mg/mL ELISA
(Detection)
Continued on next page
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Antibody Species Clone or
Cat. No.
Vendor Conju-
gate
Stock Applica-
tion*
Anti-Mouse MHC
class I
Mouse 28-14-8 eBioscience - 1 mg/mL FC
Anti-Rabbit IgG Goat sc-2030 Santa Cruz HRP 0.4 mg/mL ELISA,
WB
*ELISA - Enzyme-linked immunosorbent assay, FC - Flow cytometry, IF - Immunofluorescence,
WB - Western blot
3.1.4 Enzymes
All enzymes were used with included buffers (not listed) from the manufacturers.
Type Enzyme Vendor
DNA modifying enzymes Phusion High-Fidelity DNA Polymerase NEB
T4 DNA Ligase NEB
Miscellaneous enzymes Collagenase P Roche
RNAse A Macherey-Nagel
Protein modifying enzymes Endoglycosidas H (Endo H) NEB
Peptide-N-glycosidase F (PNGase F) NEB
Restriction enzymes BglII NEB
ClaI NEB
EcoRI NEB
KpnI NEB
NcoI NEB
NheI NEB
NotI NEB
SalI NEB
XbaI NEB
XhoI NEB
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3.1.5 Miscellaneous biologicals, chemicals and reagents
Cell culture stock media and additives
Product Vendor
β-gal497–504 peptide PSL Peptide
β-gal96–103 peptide PSL Peptide
Fetal calf serum (FCS) clone GE Healthcare
FCS standard GE Healthcare
Dulbecco’s Modified Eagle’s medium (DMEM), high glucose
(4.5 g/L), with L-Glutamine
PAN-Biotech
Iscove’s Modified Dulbecco’s medium (IMDM) with
L-Glutamine
PAN-Biotech
L-Glutamine 200 mm GE Healthcare
Mannan from Saccharomyces cerevisiae Sigma-Aldrich
Mouse serum PAN-Biotech
Non-essential amino acids 100x GE Healthcare
OptiMem Thermo Fisher Scientific
Ovalbumin Alexa Fluor 488 and 647-conjugate Thermo Fisher Scientific
OVA257–264 peptide Tebu-Bio
OVA323–339 peptide Tebu-Bio
Penicillin-Streptomycin 100x (10.000U/mL Penicillin,
10 mg/mL Streptomycin)
GE Healthcare
Recombinant human GM-CSF Immunotools
Recombinant human IL-4 Immunotools
Recombinant human M-CSF Immunotools
Roswell Park Memorial Institute (RPMI) 1640 medium
without L-Glutamine, with HEPES
PAN-Biotech
Sodium Pyruvate Solution 100 mm GE Healthcare
Transferrin Alexa Fluor 647-conjugate Thermo Fisher Scientific
Trypsin 0.05 % / EDTA 0.02 % GE Healthcare
General chemicals, biologicals and solvents
Product Vendor
3-(N-Morpholino) propane sulphonic acid (MOPS) Carl Roth
2-Mercaptoethanol ≥99 %, p.a. Carl Roth
Continued on next page
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Product Vendor
Acetic acid 100 %, p.a. Carl Roth
Bromphenol blue Carl Roth
Bovine serum albumin (BSA) Carl Roth
CaCl2 Carl Roth
Citric acid Carl Roth
Complete EDTA-free Protase Inhibitor Cocktail Roche
Ethanol (EtOH) ≥99.8 %, p.a. Carl Roth
Ethylenediaminetetraacetic acid (EDTA) disodium salt Carl Roth
Glycine Carl Roth
Isopropanol ≥99.8 %, p.a. Carl Roth
KOAc Carl Roth
KCl2 Carl Roth
K2HPO4 Carl Roth
KH2PO4 Carl Roth
KOH solution 20 % Carl Roth
Methanol (MeOH) ≥99.9 %, Blotting-Grade Carl Roth
MgCl2 Carl Roth
MgSO4 Carl Roth
MnCl2 Carl Roth
N-2-Hydroxyethyl piperazine-N’-2-ethane sulphonic acid (HEPES) Carl Roth
N,N-Bis-(2-hydroxyethyl)-2-aminoethane sulphonic acid (BES) Carl Roth
NaCl2 Carl Roth
NaHCO3 Carl Roth
NaH2PO4 Carl Roth
NaOAc Carl Roth
Phosphate-buffered saline (PBS) powder without Ca2+, Mg2+ Biochrome
Phenylmethylsulfonyl fluoride (PMSF) Carl Roth
RbCl2 Carl Roth
Tris(hydroxymethyl)-aminomethane (Tris) ≥99.9 %, p.a. Carl Roth
Microbiology
Product Vendor
Agar-agar, Kobe I Carl Roth
Ampicillin sodium salt Carl Roth
Continued on next page
25
3 METHODS
Continued from previous page
Product Vendor
Biotin Carl Roth
D-glucose Carl Roth
D-Sorbitol Carl Roth
Glycerol ≥98 %, Ph.Eur., Carl Roth
Kanamycin sulphate Carl Roth
Tryptone/Peptone ex casein Carl Roth
Yeast extract Carl Roth
Yeast nitrogen base (YNB) with ammonium sulfate, without amino acids Sigma-Aldrich
Zeocin Invivogen
Molecular biology
Product Vendor
Agarose Basic AppliChem
Deoxynucleotide (dNTP) Set, 10 mm Sigma-Aldrich
DNA-ladder (100 bp, 1 kb) NEB
Gel loading dye 6x (blue/purple) NEB
SYBR Safe DNA Gel stain Thermo Fisher Scientific
Protein biochemistry, fluorescence microscopy and flow cytometry
Product Vendor
2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
diammonium salt
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate Sigma-Aldrich
4,6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich
Acrylamide/bisacrylamide (37.5:1), 30% Carl Roth
Ammonium persulfate (APS) Carl Roth
Collagen R Serva
Color Prestained Protein Standard, Broad Range
(11 kDa–245 kDa)
NEB
ECL Western blotting substrate Pierce
Fluoromount Aqueous Mounting Medium Sigma-Aldrich
Imidazole ≥99 % Carl Roth
Continued on next page
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Product Vendor
Mouse IFN-γ/IL-2/IL-6/IL-12/TNF-α, recombinant ELISA
standard
eBioscience
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Carl Roth
NeutrAvidin Protein horseradish peroxidase (HRP) conjugate Pierce
Ovalbumin Serva
Paraformaldehyde (PFA) Carl Roth
Protein G chromatography cartridge (1 mL) Pierce
Protino nickel-nitrilo-triacetic acid (Ni-NTA) agarose Macherey-Nagel
Polyoxyethylene-20-sorbitan monolaurate (Tween 20) Carl Roth
Polyethylene glycol alkylphenyl ether (Triton X-100) Carl Roth
Powdered milk, blotting grade, low fat Carl Roth
Roti-Blue Carl-Roth
Roti-Quant Carl Roth
Sephacryl S200 HR Sigma-Aldrich
Sodium dodecyl sulfate (SDS), 20% Carl Roth
3.1.6 Kits
Kit Vendor Application
EasySelect Pichia Expression
Kit
Thermo Fisher Scientific P. pastoris strains and protocols
NuceloBond Xtra Midi Macherey-Nagel Mid-scale DNA preparation
NucleoSpin Gel and PCR
Clean-up
Macherey-Nagel DNA extraction from agarose
gels, general DNA clean up
Pierce BCA Protein Assay
Kit
Thermo Fisher Scientific Protein concentration
determination by bicinchoninic
acid (BCA) assay
3.1.7 Buffers and solutions
If not otherwise declared, all buffers and solutions were prepared with autoclaved Milli-Q
Type 1 ultrapure water and solutions were sterilized by autoclaving for 20 min at 121 ◦C
or filtration through 0.2 µm cellulose acetate or polyvinylidene fluoride filters and stored
at room temperature (RT).
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General stock solutions
Solution Composition
EDTA 0.5m 500 mm EDTA in H2O, pH 7.6, filter sterilized
EDTA 2m EDTA 0.5m diluted in sterile PBS, stored at 4 ◦C
Phosphate buffered saline
(PBS)
8000 mg/L NaCl, 200 mg/L KCl, 1150 mg/L Na2HPO4,
200 mg/L KH2PO4, pH 7.4
Microbiology
Solution Composition
Biotin 500x (0.02 %) 20 mg biotin in 100 mL H2O, filter sterilized, stored at
4 ◦C
Breaking buffer 50 mm sodium phosphate, pH 7.4, 1 mm PMSF, 1 mm
EDTA, 5 % glycerol
Dextrose 10x (20 %) 200 g d-glucose in 1 L H2O
Glycerol 10x (10 %) 10 % (v/v) glycerol in H2O
TFBI 10 mm CaCl2, 15 % (v/v) glycerol, 30 mm KOAc pH
5.8, 100 mm RbCl2, 50 mm MnCl2
TFBII 10 mm MOPS pH 7.0, 10 mm RbCl2, 75 mm CaCl2,
15 % (v/v) glycerol
Potassium phosphate buffer 1m 132 mL of 1m K2HPO4, 868 mL of 1m KH2PO4, pH
6.0 ± 0.1 adjusted with KOH
YNB 10x 134 g/L YNB in H2O, filter sterilized
Molecular biology
Solution Composition
Mini-prep buffer I Tris/HCl pH 8, 50 mm EDTA 10 mm, 100 µg/mL RNaseA, stored
at 4 ◦C
Mini-prep buffer II 200 mm NaOH, 1 % (v/v) SDS
Mini-prep buffer III 3m KOAc, pH 5.5
Tris-acetate-EDTA
(TAE) 50x
2m Tris, 1m acetic acid, 0.05m EDTA , pH 8,3
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Protein biochemistry
Solution Composition
ABTS buffer 0.1m Citric acid, pH 4.35, stored at 4 ◦C.
AP substrate buffer 100 mm Tris-HCl, 100 mm NaCl, 1 mm MgCl2, pH 9.5,
stored at 4 ◦C
DNP 50 mm NaH2PO4, 300 mm NaCl, 8m urea pH 8
DNPI-10/20/250 50 mm NaH2PO4, 300 mm NaCl, 8m urea,
supplemented with 10, 20 or 250 mm imidazole, pH 8
ELISA blocking buffer 1 % (w/v) BSA in PBS
ELISA coating buffer 0.1m NaHCO3 in H2O, pH 8.2, stored at 4 ◦C
ELISA washing buffer 0.05 % Tween 20 in PBS
Fc-chimeric coating buffer 154 mm NaCl inH2O
Laemmli buffer 4x 250 mm Tris-HCl (pH = 6,8), 8 % (v/v) SDS, 40 %
(v/v) glycerol, 0.08 % (w/v) Bromphenol blue, 10 %
2-Mercaptoethanol
NP 50 mm NaH2PO4, 300 mm NaCl pH 8
NPI-10/20/250 50 mm NaH2PO4, 300 mm NaCl supplemented with
10, 20 or 250 mm imidazole, pH 8
PBST PBS, 0.05 % Tween 20
Protein G binding buffer 50 mm NaOAc, pH 5
Protein G elution buffer 0.1m Glycine inH2O,pH 2.88
Protein G neutralization buffer 1m Tris, pH 8.5
SDS running buffer 10x 250 mm Tris, 1.92m glycine, 1 % (v/v) SDS
Tris buffered saline (TBS) 10x 500 mm Tris, 1.5m NaCl, pH 7.5
TBST TBS, 0.05 % Tween 20
TBSTC TBST, 10 mm CaCl2
Towbin buffer 25 mm Tris, 192 mm glycine, pH 8.3
Flow cytometry/Fluorescence microscopy
Solution Composition
FACS buffer 0.1 % (w/v) BSA, 0.1 % (w/v) NaN3 in PBS, stored at 4 ◦C
Fixation buffer 4 % (w/v) PFA in PBS
Intracellular staining buffer 0.1 % Triton X-100, 5 % appropriate serum (mouse, rabbit
or goat) in PBS
MACS buffer FACS buffer, 2 mm EDTA
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3.1.8 Media
Cell culture media
Medium Composition
Bone marrow-derived
dendritic cell (BM-DC)
culture medium
IMDM, 10 % heat inactivated FCS clone, 100U/mL
penicillin and 0.1 mg/mL streptomycin, 50 mm
2-Mercaptoethanol
BM-DC uptake medium IMDM, 10 % heat inactivated FCS clone, 100U/mL
penicillin and 0.1 mg/mL streptomycin, 50µm
2-Mercaptoethanol, 2.5 % J558L conditioned medium
Human embryonic kidney
(HEK) cell medium
DMEM, 10 % heat inactivated FCS standard, 1 mm sodium
pyruvate
J558L medium RPMI 1640, 10 % heat inactivated FCS clone, 100U/mL
penicillin and 0.1 mg/mL streptomycin
T cell medium RPMI 1640, 10 % heat inactivated FCS clone, 50µm
2-Mercaptoethanol, 100U/mL penicillin and 0.1 mg/mL
streptomycin, 1 mm sodium pyruvate
Microbiology media
If not otherwise declared, all microbiology media were prepared with autoclaved Milli-Q
Type 1 ultrapure water.
Medium Composition
BMGY 10 g/L yeast extract, 20 g/L tryptone/peptone, 100 mm
potassium phosphate buffer pH 6.0, 1.34 % YNB, 4× 10−5 %
biotin, 1 % glycerol, filter sterilized
BMMY 10 g/L yeast extract, 20 g/L tryptone/peptone, 100 mm
potassium phosphate buffer pH 6.0, 1.34 % YNB, 4× 10−5 %
biotin, 0.5 % MeOH, filter sterilized
LB medium 5 g/L NaCl, 5 g/L yeast extract, 10 g/L tryptone/peptone,
autoclaved 20 min at 121 ◦C and stored at 4 ◦C
YB medium 2x 5 g/L NaCl, 10 g/L yeast extract, 16 g/L tryptone/peptone,
pH 7.5, autoclaved 20 min at 121 ◦C and stored at 4 ◦C
YT medium 98 % YT-Media, 10 mm KCl, 20 mm MgSO4 autoclaved
20 min at 121 ◦C and stored at 4 ◦C
YPD 10 g/L yeast extract, 20 g/L tryptone/peptone, 2 % dextrose
Continued on next page
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Medium Composition
YPDS-Agar 10 g/L yeast extract, 20 g/L tryptone/peptone, 1m sorbitol,
2 % dextrose, 2 % (w/v) agar
YPM-Agar 10 g/L yeast extract, 20 g/L tryptone/peptone, 2 % (w/v)
agar, 0.5 % MeOH
3.1.9 Bacteria and yeast strains, cell lines and mice strains
Yeast strains
Genus Strain Genotype Description
Pichia pastoris KM71H aox1::ARG4, arg4 MutS phenotype
Bacteria
Genus Strain Genotype
Escherichia coli DH5α F- ΦlacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1
hsdR17 (rK-, mK+) phoA supE44 λ- thi-1 gyrA96 relA1
Escherichia coli XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’
proAB lacI qZΔM15 Tn10 (Tetr)]
Cell lines
Cell line Description
HEK293T HEK cells constitutively expressing the SV40 large T antigen
HEK-MR HEK293T cells transfected with MR-internal ribosome entry site
(IRES)-GFP [125]
HEK-IG HEK293T cells transfected with IRES-GFP [125]
J558L-GM-CSF Transgenic myeloma cell line received from BALB/c mice, constitutively
secretes mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF), G418 selectable
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Mice
Mouse
strain
Description Background
C57BL/6J Wild-type strain C57BL/6J
DesTCR Express a Kb-specific T cell receptor (KB5.C20 TCR) on
CD8+ thymocytes [126]
B10.BR
OT-I Bear CD8+ T cells, which have a TCR specific for the
ovalbumin peptide OVA257–264 in the context of Kb [127, 128]
Rag2-/-
OT-II Bear CD4+ T cells recognizing the ovalbumin peptide
OVA323–339 on I-Ab MHC-II molecules [129]
C57BL/6J
MR-/- Bears a stop codon inserted at the Mannose receptor start
codon of Exon 1, which abolishes the expression of MR [88]
C57BL/6J
3.1.10 Primers and plasmids
Primers
All primers were ordered from Thermo Fisher Scientific (formally Life Technologies)
under the brand of InvitorgenTM custom DNA oligos.
Name Sequence
oCK1 GACAGTGGATCCTTATGGCTCGCGATGATCCC
oCK2 TACGTACTGCAGACATGGCCTGCCCGGTTA
oCK3 CCAAGCTCGAAATTAACCCTCAC
oCK9 TAGCGGATCCAGATGAGTCTTGGAGGTGTTTC
oCK16 CAGTGTCGACGTGATTACGATCGCGCTGCA
oCK26 GATCCCATGGATTACAAGGATGACGACG
oCK27 GCTCAGATCTCAATGATGATGATGATGATGG
oCK41 CAGCATCGATGGGTAATTCTACTATGGGTACCTGCAGTCGACTTCTA
GACTCGAGTAGC
oCK42 GCTACTCGAGTCTAGAAGTCGACTGCAGGTACCCATAGTAGAATTAC
CCATCGATGCTG
oCK45 CATAGGTACCATGGTGAGCAAGGGC
oCK46 CAGTTCTAGACTTGTACAGCTCGTCC
oCK47 CAGCATCGATGGGTCAATCTACTATGGGTACCTGCAGTCGACTTCTA
GACTCGAGTAGC
Continued on next page
32
3 METHODS
Continued from previous page
Name Sequence
oCK48 GCTACTCGAGTCTAGAAGTCGACTGCAGGTACCCATAGTAGATTGAC
CCATCGATGCTG
oCK49 GCGCGAATTCGGGCGGAGGTAATTCTACTATGGGTACC
oCK50 GCGCGAATTCGGGCGGAGGTCAATCTACTATGGGTACC
oCK51 CGATGCTAGCTCAATGATGATGATGATGATGG
oCK56 CAGTTCTAGAGGCTGACATATGCTTGTACAGCTCGTCCATGC
oCK57 TATGTCAGGCCTTGAGCAGCTTGAGAGTATAATCAACTTTGAAAAAC
TGACTGAATGGACCAGTTCTT
oCK58 CTAGAAGAACTGGTCCATTCAGTCAGTTTTTCAAAGTTGATTATACTC
TCAAGCTGCTCAAGGCCTGACA
Plasmids
Maps of all plasmids which were generated during this work are provided in the appendix.
Name Resistance Description Origin
pIgplus-MR-
CTLD
Ampicillin Secreted expression of MR-CTLD
by HEK293T cells
Luisa
Martinez-Pomares
pIgplus-MR-
Nterm
Ampicillin Secreted expression of MR-Nterm
by HEK293T cells
Luisa
Martinez-Pomares
pFUSE-
hIgG1-Fc2
Zeocin Secreted expression of Fc-control
by HEK293T cells
Invivogen
pBS-IRES-
NLS-lacZ
Kanamycin Source of Escherichia coli (E. coli)
lacZ
Dr. Christina Ginkel,
DZNE, Bonn
pCMV-Tag2B Kanamycin Cloning intermediate for addition
of FLAG-tag
Clontech
pCMV-Tag2B-
EGFP
Kanamycin Source of EGFP AG Burgdorf, LIMES,
University of Bonn
pQE60 Ampicillin E. coli expression plasmid Quiagen
pPICZα C Zeocin P. pastoris expression plasmid for
secreted expression
Invitrogen
pPICZα-NST Zeocin P. pastoris expression plasmid for
secreted NST-tagged expression
created during this
work
pPICZα-QST Zeocin P. pastoris expression plasmid for
secreted QST-tagged expression
created during this
work
Continued on next page
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Name Resistance Description Origin
pCK1 Kanamycin Cloning intermediate, source of
FLAG-tagged lacZ
created during this
work
pCK15 Zeocin Secreted expression of truncated
β-galactosidase (β-gal)(V10–H451)
by P. pastoris
created during this
work
pCK27 Zeocin Secreted expression of truncated
β-gal(V10–L731) by P. pastoris
created during this
work
pCK44 Zeocin Expression of truncated
β-gal(V10–L731) by E. coli
created during this
work
pCK45 Zeocin Secreted expression of NST-tagged
GFP by P. pastoris
created during this
work
pCK50 Zeocin Secreted expression of QST-tagged
GFP by P. pastoris
created during this
work
pCK51 Zeocin Secreted expression of NST-tagged
GFP by HEK293T cells
created during this
work
pCK52 Zeocin Secreted expression of QST-tagged
GFP by HEK293T cells
created during this
work
pCK57 Zeocin Secreted expression of NST-tagged
GFP with C-terminal SIINFEKL
by P. pastoris
created during this
work
3.1.11 Software
Software Distributor Application
Ascent Software Thermo Scientific Computer assisted control and data
acquisition with Multiskan plate reader
AxioVision ZEISS Fluorescence microscopy data acquisition and
image processing
BD FACSDiva BD Bioscience Flow cytometry data acquisition
CloneManager 5 Sci-Ed In silico cloning and vector visualization
Excel Microsoft Data analysis
FlowJo v8.8.4 FlowJo, LLC Flow cytometry data analysis and
visualization
Continued on next page
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Software Distributor Application
FluorEssence Horiba Computer assisted control and data
acquisition with FluoroMaxx-4
spectrofluorometer
i-control Tecan Data acquisition Tecan microplate reader
Illustrator CS4 Adobe Data visualization
Image Lab Bio-Rad Computer-assisted control and data
acquisition with ChemiDoc MP System
ImageJ64 Open source under the
GNU General Public
License.
Image processing and visualization
NanoDrop 2000 /
2000c Software
Thermo Scientific Computer-assisted control and data
acquisition with NanoDrop 2000
Prism 4 GraphPad Data analysis and visualization
PyMol Schro¨dinger Visualization of PDB files
R Studio R Studio, Inc R based statistical analysis
This thesis was typeset using the LaTeX typesetting system originally developed by
Leslie Lamport, based on TeX created by Donald Knuth.
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3.2 Methods
3.2.1 Molecular biology
3.2.1.1 Polymerase chain reaction (PCR)
Amplification of nucleic acids from plasmid DNA was performed by standard PCR using
the high fidelity polymerase Phusion according to the manufacturer’s manual. In short,
a 50 µL reaction was set up on ice as indicated in Table 3.1.
Table 3.1: Cycling conditions
Component 50µL reaction
H2O added to 50µL
5x Phusion HF Buffer 10 µL
10 mm dNTPs 1 µL
Primer A 0.5 µm
Primer B 0.5 µm
Template 10 ng
DNA Polymerase 0.5 µL
Primer melting temperatures (Tm) were calculated using NEB’s Tm-calculator v1.8.1
(online at http://tmcalculator.neb.com/#!/) and according to the temperatures a
2- or 3-step protocol as indicated in Table 3.2 was run on a thermocycler.
Table 3.2: Reaction setup
2-step protocol 3-step protocol
Cycle step Temperature Time Temperature Time Cycles
Initial
denaturation
98 ◦C 30 s 98 ◦C 30 s 1
Denaturation 98 ◦C 10 s 98 ◦C 10 s 35
Annealing — — calculated Tm 20 s 35
Extension 72 ◦C 15–30 s/kb 72 ◦C 15–30 s/kb 35
Final
extension
72 ◦C 600 s 72 ◦C 600 s 1
4 ◦C hold 4 ◦C hold
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3.2.1.2 Restriction digestion
Restriction reactions were generally set up according to the manufacturer’s manual.
Differing from standard protocols, analytical restriction digestions were performed with
100–300 ng DNA and 0.1–0.3U restriction enzyme in the corresponding buffer system,
incubated for 1–2 h at the indicated temperature and analyzed directly by gel elec-
trophoresis without enzyme inactivation. Preparative restriction digestions were typi-
cally performed with 1–2µg DNA template and 10-fold overdigestion by increasing the
incubation time to 16 h if possible or increasing enzyme concentration to 10–20U if
prolonged incubation goes along with star activity.
3.2.1.3 Gel electrophoresis
Separation of nucleic acids was done by agarose gel electrophoresis. Briefly, agarose
gels were prepared by solving 1 % (w/v) low melting agarose in 1x TAE buffer. For
low molecular weight DNA < 1 kb gels were prepared with 2 % (w/v) agarose. For
better resolution of high molecluar weight DNA > 4 kb gels were prepared with 0.8 %
(w/v) agarose. After boiling the gel solution in a microwave oven to homogeneity, the
gels were cooled below 50 ◦C and supplemented with 1:20,000 dilution (v/v) of SYBR
Safe. Gels were poured at sizes and with a number of lanes as needed for the particular
experiment. After polymerization, gels were mounted in a Bio-Rad horizontal Mini-
Sub Cell GT system and covered with 1x TAE. DNA samples were supplemented with
1x gel loading dye prior loading and 6µL of a 1 kb or 100 bp ladder were applied as
size indicators. Electrophoresis was performed at 7 V/cm. Gels were investigated on a
470 nm light table. If needed, DNA was cut out for further processing and gels were
photographed for documentation.
3.2.1.4 DNA purification
DNA purification from solutions (PCR or restriction digestion reactions) or agarose gels
was performed by NucleoSpin Gel & PCR Clean Up Kit (Macherey-Nagel) according
to the manufacturer’s manual. Differing from the manual, samples were eluted in 16µL
ultrapure H2O. If Vector DNA was cut within the multiple cloning site (MCS) and
the fragment to be removed was smaller than 100 nucleotides in length, digested vector
DNA was not separated by gel electrophoresis first but directly purified with the kit. In
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this case the loading buffer was adjusted as recommended in the manual with ultrapure
H2O to exclude binding of small fragments.
3.2.1.5 DNA quantification
DNA concentration was determined by absorption at 260 nm with a NanoDrop 2000 spec-
trophotometer against ultrapure H2O as a blank. Purity was determined by A260/A280
to monitor protein contamination.
3.2.1.6 DNA ligation
Ligation was performed with NEB’s T4 DNA Ligase according to the manufacturer’s pro-
tocol for cohesive ends. Briefly, 250 fmol insert were mixed with 50 fmol vector backbone,
1x T4 DNA ligase reaction buffer and 1 µL T4 DNA Ligase (400U) and the reaction
was filled up with ultrapure H2O to 20 µL. Ligation was carried out for 10–15 min at
RT, and the enzyme was inactivated for 10 min at 65 ◦C.
3.2.1.7 Generation of transformation competent Escherichia coli strains
Generation of chemically competent Escherichia coli (E. coli) was performed according
to the rubidium chloride method introduced by Hanahan 1983 [130]. In short, a 3 mL
LB-culture was inoculated with a single DH5α or XL1-Blue E. coli clone and incubated
overnight at 37 ◦C. This starter culture was used to inoculate 100 mL YB medium,
which was grown at 37 ◦C up to an OD600 of 0.4–0.6. Bacteria were harvested by
centrifugation (10 min, 3,220 x g, 4 ◦C), resuspended in 20 mL TFB I and incubated on
ice for 10 min. Bacteria were harvested again by centrifugation (10 min, 3,220 x g, 4 ◦C)
and resuspended in 4 mL TFB II. 200µL aliquots were frozen in liquid nitrogen and
stored until use at −80 ◦C.
3.2.1.8 Transformation
50 µL chemical competent DH5α or XL1-Blue E. coli were used for each transformation.
Cells were thawed on ice and incubated with 2–8 µL of a 20 µL ligation reaction for
30 min on ice, before a heat-shock was performed for 90 sec at 42 ◦C. Afterwards, cells
were resuspended in 1 mL LB-media without antibiotics and incubated for 1 h at 37 ◦C
and 600 rpm in a shaking heat block. The cells were harvested by centrifugation (1 min,
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21,000 x g), resuspended in 50–100 µL LB-medium and spread on 10 cm LB-agarose
plates, including the appropriate antibiotics for positive selection. Ampicillin was used at
100 µg/mL, kanamycin at 50µg/mL and zeocin at 25 µg/mL for selection. Transformants
were incubated at 37 ◦C overnight.
3.2.1.9 Mini-preparation of plasmid DNA
Single clones on LB-agar plates were used to inoculate 3 mL LB-medium supplemented
with the respective antibiotics in a 15 mL conical tube. After incubation at 37 ◦C and
180 rpm overnight, 1.5 mL of each culture was transferred to an 1.5 mL reaction tube,
and cells were collected by centrifugation (21,000 x g, 5 min). Supernatant was discarded
and pellets were resuspended in 100µL Mini-prep buffer I. Alkaline cell lysis was started
by adding 200 µL Mini-prep buffer II. Samples were mixed 3 times by inverting and
incubating for 5 min at RT. Cell lysis was stopped and proteins were precipitated by
adding 200µL Mini-prep buffer III followed by inverting 3 times. Precipitated protein
was collected by centrifugation (21,000 x g, 5 min). The supernatants were carefully
transferred to a fresh tube and 1 mL ice-cold 100 % EtOH was added to precipitate DNA.
Precipitation and collection of the DNA precipitate was carried out by centrifugation
(21,000 x g, 30 min) at 4 ◦C. Supernatants were removed, and DNA-pellets were washed
once with 1 mL ice-cold 70 % EtOH (v/v) in ultrapure H2O. Pellets were harvested
again by centrifugation (21,000 x g, 10 min), and supernatants were fully removed by
pipetting. Pellets were dried at RT and subsequently resuspended in 50µL ultrapure
H2O.
3.2.1.10 Midi-preparation of plasmid DNA
For mid-scale preparation of plasmid DNA (Midi-preparation), 3 mL LB-medium sup-
plemented with the appropriate selection antibiotics were inoculated with a single clone
in a 15 mL conical tube and incubated overnight at 37 ◦C and 180 rpm. 1 mL of this
starter culture was used to inoculate 100–200 mL LB-medium supplemented with the
selection antibiotics and this culture was incubated overnight at 37 ◦C and 180 rpm
in a 500–1000 mL flask. Bacteria pellets were harvested by centrifugation (3,220 x g,
20 min, 4 ◦C), and DNA preparation was performed using the NuceloBond Xtra Midi kit
(Macherey-Nagel) according to the manufacturer’s manual.
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3.2.1.11 Sequencing
All sequencing reactions were performed by GATC biotech (Konstanz, Germany) with
self-designed primers or standard primers provided by GATC biotech. Analysis of
FASTA sequencing data was performed with Clone Manager 5 software (Scie-Ed), and
evaluation of primary peak data was performed with 4Peaks software (nucleobytes).
3.2.1.12 Cloning strategies for expression plasmids
Quality of all generated plasmids was controlled by restriction digestion and sequencing.
Plasmid maps are provided in the appendix.
pCK27 — pPICZα-FLAG::β-gal(V10–L731)
The wildtype lacZ gene from E. coli was amplified via PCR with oCK1 and oCK2 from
the template plasmid pBS-IRES-NLS-lacZ (gift from Christina Ginkel, DZNE, Bonn).
The PCR product was digested with BamHI and PstI and ligated into the FLAG-tag
containing plasmid pCMV-Tag2C to yield the intermediate plasmid pCK1. Another
PCR was performed with pCK1 as a template with primers oCK3 and oCK9, which
amplified a truncated version of lacZ starting with the FLAG-tag and comprising the
β-galactosidase residues V10–L731. The PCR product was cloned via the SalI and NotI
restriction sites into the pPICZα C expression plasmid.
pCK44 — pQE60-FLAG::β-gal(V10–L731)
The truncated lacZ gene from pCK27 was amplified with primers oCK26 and oCK27
via PCR and cloned into pQE60 via NcoI and BglII restriction sites.
pPICZα-NST and pPICZα-QST
2 µg of the oligos oCK41 and oCK42 (for pPICZα-NST) or oCK47 and oCK48 (for
pPICZα-QST) were mixed in 50µL ultrapure H2O and heated for 5 min at 95 ◦C. The
mixture was then slowly cooled (∼45 min) to room temperature for annealing. The
annealed DNA-oligos were digested with ClaI and XhoI and then ligated into pPICZα
C, which was digested with ClaI and SalI, thereby destroying the original SalI site in
pPICZα C.
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pCK45 — pPICZα-NST-EGFP and
pCK50 — pPICZα-QST-EGFP
EGFP was amplified from pCMV-Tag2B-EGFP (gift from Matthias Zehner, Univer-
sity of Bonn) with primers oCK45 and oCK46. The PCR product was digested with
KpnI and XbaI and ligated into pPICZα-NST (pCK45) or pPICZα-QST (pCK50) in
order to generate NST-tagged or QST-tagged EGFP (NST-GFP, QST-GFP).
pCK51 — pFUSE-hIgG1-NST::EGFP::6xHis and
pCK52 — pFUSE-hIgG1-QST::EGFP::6xHis
NST-tagged or QST-tagged EGFP was amplified with oCK49 and oCK51 or oCK50
and oCK51, respectively via PCR from pCK45. The PCR products were ligated into
pFUSE-hIgG1-Fc2 via EcoRI and NheI by which the hIgG1 part was removed. NST-
tagged EGFP is encoded by pCK51, QST-tagged EGFP by pCK52.
pCK57 — pPICZα-NST-EGFP-S8L
EGFP was amplified from pCMV-Tag2B-EGFP (gift from Matthias Zehner, Univer-
sity of Bonn) with primers oCK45 and oCK56. The PCR product was digested with
KpnI and NdeI and ligated into pPICZα-NST (pCK45). Complementary oligos oCK57
and oCK58 were used to introduce the OVA epitope SIINFEKL (S8L) into the resulting
plasmid via NdeI and XbaI.
pCK15 — pPICZα-FLAG::β-gal(V10–H451)
A truncated β-gal(V10–H451) was amplified via PCR with primers oCK3 and oCK16
from pCK1 as a template. The product was cloned into pPICZα C via SalI and NotI
restriction sites.
3.2.2 Cell culture
All cell culture handling and experiments were performed under sterile working condi-
tions and under mycoplasma-free conditions, as documented by frequent testing with a
mycoplasma detection kit (PAA/GE Healthcare). If not otherwise declared, cell lines
and primary cells were incubated in separate incubators at 37 ◦C and 90 % humidity
with 5 % CO2 saturation, and all media and solutions were pre-warmed to 37 ◦C before
use.
41
3 METHODS
3.2.2.1 Cultivation HEK293T cells
All types of HEK cells (HEK293T, HEK293T-IG and HEK293T-MR) were cultured in
15 mL HEK cell medium on 10 cm tissue culture treated plates (Sarstedt) and either
freshly thawed and expanded once or kept at low passages (< 15) for the experiments.
Passaging was performed every 2–3 days, when cells reached 60–70 % confluence by
incubation for 1 min at 37 ◦C in 0.05 % Trypsin/0.02 % EDTA solution (PAA). Cells
were detached from the plate by pipetting with additional 9 mL HEK cell medium and
collected by centrifugation (300 x g, 5 min, RT). Cells were then resuspended in 10 mL
and distributed on fresh plates with fresh HEK Medium.
3.2.2.2 J558L conditioned medium
J558L-GM-CSF cells were freshly thawed for the generation of conditioned medium.
1× 106 cells were plated in 30 mL J558L-medium per 15 cm plate and incubated for
8–10 days. Supernatants were collected and filtered through 0.2µm cellulose acetate
filters. GM-CSF content was determined by ELISA, and aliquots of 50 mL were frozen
at −20 ◦C.
3.2.2.3 In vitro generation and cultivation of bone marrow-derived dendritic cells
(BM-DCs)
BM-DCs were in principle generated as previously described [131, 132]. In short, mice
were first anesthetized with isofluran and then euthanized by cervical dislocation. The
hind limbs of the mice were isolated, and bones were rinsed with PBS to collect the
bone marrow. Bone marrow was disaggregated rigorously by pipetting to get a single
cell suspension. Cells were collected by centrifugation (300 x g, 5 min, RT) and resus-
pended in 45 mL BM-DC culture medium, which contains J558L conditioned medium
as a GM-CSF source. Cells were spread on 3 untreated petri dishes and incubated for 3
days. Thereafter, supernatants containing swimming cells were collected, and adherent
cells were detached with 2 mm EDTA in PBS. All cells were combined, harvested by
centrifugation (300 x g, 5 min, RT), resuspended in 90 mL BM-DC culture medium and
spread on 6 untreated petri dishes. Cells were incubated until their use on day 7–8 post
isolation.
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3.2.2.4 In vitro culture of human DCs and macrophages from human peripheral
blood mononuclear cells (PBMCs)
In vitro generation was performed by Susanne V. Schmidt and Lan Do (AG Schultze,
LIMES, University of Bonn) as previously described [133]. Briefly, PBMCs were isolated
by Ficoll (1.077 g/mL) gradient centrifugation from buffy coats. CD14+ human mono-
cytes were further purified from PBMCs by magnetic-activated cell sorting (MACS)
(Miltenyi biotec) following the manufacturer’s manual. Macrophages were differentiated
from these monocytes by incubation in RPMI 1640, supplemented with 10 % FCS and
1 % PenStrep solution in the presence of 50 IU/mL macrophage colony-stimulating factor
(M-CSF) for 72 h. PreDCs were generated by incubation with 500 IU/mL recombinant
human GM-CSF and 800 IU/mL recombinant human interleukin-4 (IL-4) in RPMI 1640
supplemented with 10 % FCS and 1 % PenStrep solution for 72 h.
3.2.3 Protein expression in bacteria, yeasts and mammalian cells
3.2.3.1 Protein expression in E. coli
Chemically competent E. coli cells were transformed with pCK44, as described under
section 3.2.1.8. A single clone was used to inoculate 20 mL LB-medium supplemented
with 100 µg/mL ampicillin in a 50 mL conical tube, which was incubated overnight at
37 ◦C and 180 rpm. This starter culture was used to inoculate 2 L LB-medium supple-
mented with 100 µg/mL ampicillin. The culture was incubated at 37 ◦C and 160 rpm
until an OD600 of 0.5–0.7 was reached. Induction was then started by adding 1 mm
IPTG. After incubating 4 h at 37 ◦C and 160 rpm, the culture was harvested by centrifu-
gation (6,000 x g, 20 min, 4 ◦C). The pellet was washed once with NP-buffer, frozen in
dry ice-ethanol and stored at -20 ◦C until used for protein purification.
3.2.3.2 Electroporation of P. pastoris
Electroporation-competent P. pastoris KM71H cells were prepared according to the
guidelines of the EasySelect Pichia Expression Kit manual (Invitrogen, ThermoFisher
Scientific). 80µL of the prepared competent cells were mixed with 10 µg PmeI-linearized
plasmid DNA in 10µL sterile water and incubated in a 0.2µm electroporation cuvette on
ice for 5 min. Cells were pulsed with the Bio-Rad Gene Pulser Xcell electroporation de-
vice with 1500 V, 25 µF and 200 Ω and resuspended in 1 mL of ice-cold 1m sorbitol. This
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solution was transferred to a 15 mL conical tube and incubated at 30 ◦C without shak-
ing for 1 h before spreading on YPDS agar plates containing 100µg/µL zeocin. Plates
were incubated for 3–10 days at 30 ◦C until colonies became visible. Single colonies were
then transferred to a fresh YPD-agar plate supplemented with 100 µg/µL zeocin and
numbered for screening purposes.
3.2.3.3 Screening of β-galactosidase secreting P. pastoris clones
Screening plates were transferred with a replicator stamp onto a methanol-containing
YP-agar plate (YPM). Induction was carried out for 3 days at 30 ◦C and maintained
by the addition of a few drops 100 % MeOH every 24 h to the plate lid to account for
evaporating MeOH. Secreting clones were then identified by yeast colony western blot as
described previously [134]. 2–6 clones that showed strong western blot signal were then
used to inoculate 2 mL BMGY in a 15 mL conical tube and were incubated overnight
at 30 ◦C and 180 rpm to generate biomass. The culture was harvested by centrifugation
(3,220 x g, 10 min, RT) and induced in 1 mL BMMY. Cultures were incubated for 96 h
at 30 ◦C and 180 rpm. Induction was maintained by adding 1 % (v/v) MeOH every
24 h. Pellets and supernatants were separated by centrifugation (13,000 x g, 5 min).
Proteins from pellets were extracted with glass beads as described in the EasySelect
Pichia Expression Kit manual, and pellet extracts and supernatants were analyzed for
protein expression by SDS-gel electrophoresis and western blot to verify the yeast colony
western blot. Positive β-galactosidase secreting clones were streaked out on fresh YPD
plates, supplemented with 100µg/mL zeocin as a source of single clones for protein
expression.
3.2.3.4 Screening of GFP-derivatives secreting P. pastoris clones
Clones from a screening plate were directly used to inoculate 200 µL BMMY supple-
mented with 100µg/mL ampicillin in a 96-well transparent round bottom plate. Plates
were covered and incubated at 30 ◦C, 140 rpm overnight. Cells were harvested by cen-
trifugation (3,220 x g, 10 min, RT) and resuspended in 100µL NP-buffer supplemented
with 2 % (v/v) MeOH. Plates were incubated for additional 3 days at 30 ◦C and 140 rpm
and re-induced every 24 h by adding 2 % (v/v) MeOH. Supernatants were harvested by
centrifugation (3,220 x g, 10 min, RT), and supernatants were transferred to a black
FLUOTRAC plate. Plates were illuminated with a blue LED on the Bio-Rad Chemi-
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Doc system, using the Alexa 488 filter for optical detection. Additionally, emission at
525/20 nm was detected after excitation at 485/25 nm. The presence of recombinant
GFP-proteins in the supernatant was additionally validated by western blot against the
His-tag. As for β-galactosidase clones, positive GFP secreting clones were streaked out
on fresh YPD plates supplemented with 100µg/mL zeocin.
3.2.3.5 Large-scale protein expression in P. pastoris
A single clone of the desired P. pastoris transformant was used to inoculate 20 mL YPD-
medium supplemented with 100 µg/mL ampicillin. After incubation overnight at 30 ◦C
and 180 rpm this starter culture was used to inoculate 4 L BMGY that were separated on
four 5 L baffled flasks. The biomass culture was supplemented with 100 µg/mL ampicillin
and 10 µL antifoam and incubated overnight at 30 ◦C and 120 rpm until OD600 reached
5–6. Cells were harvested by centrifugation (3,000 x g, 8 min, RT) and resuspended in
400 mL NP-buffer supplemented with 100µg/mL ampicillin and 10µL antifoam. This
suspension was split on two 2 L flasks (200 mL each), and 2 % (v/v) MeOH were added
for induction. Cultures were incubated for 48–72 h in the case of GFP variants, or
for 72–96 h in the case of β-galactosidase at 30 ◦C and 140 rpm. 1 % (v/v) MeOH was
added every 24 h to re-induce the culture. Finally, supernatants were harvested by
centrifugation (20,000 x g, 15 min, 4 ◦C) and filtered through a 0.2µm cellulose acetate
filter. From here on solutions were kept on ice and directly processed for purification.
3.2.3.6 Calcium phosphate transfection of HEK293T cells
3× 106 HEK293T cells were plated in 10 mL HEK medium in a T75 flask and incu-
bated overnight. Medium was aspirated and cells were washed once with PBS before
10 mL fresh HEK cell medium were added. Cells were incubated for at least 1 h. For
the generation of DNA-precipitates, 10µg plasmid DNA were mixed with 1m CaCl2
and ultrapure H2O to adjust 0.25m CaCl2 in 500µL. This solution was mixed with
500 µL 2x BBS by vortexing and was incubated for 5–20 min at RT before adding to the
HEK293T cells. Cells and precipitates were incubated overnight before the supernatant
was aspirated, and cells were washed twice with 5 mL PBS. For protein production, cells
were incubated for another 72 h in 20 mL OptiMem. Before proceeding with protein
purification, supernatants were harvested by centrifugation (10 min, 3,220 x g, 4 ◦C) and
filtered through a 0.2µm cellulose acetate filter.
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3.2.4 Protein purification
3.2.4.1 Purification of recombinant His-tagged β-galactosidase from P. pastoris
supernatants
The 400 mL filtered supernatants from large-scale expression cultures were concentrated
by tangential filtration through a 30 kDa cut-off Hydrosart membrane to roughly 20–
40 mL, and the concentrate was washed twice with fresh NP-buffer. The solution was
further concentrated by ultrafiltration with a 15 mL Amicon centrifuge device (30 kDa
cut-off) to a volume of 4 mL. The concentrate was adjusted with NPI-20 and 1 %Triton
X-100 in NP-buffer to 10 mm imidazole and 0.1 % (v/v) Triton X-100. This solution was
batch-purified on 2 mL settled Ni-NTA agarose (Macherey-Nagel) mainly as described
in the section for native purification in the manufacturer’s manual. Briefly, 2 mL bed
volume Ni-NTA beads were washed 5 times in a 15 mL conical tube with 10 mL NPI-
10. Afterwards, the protein-containing solution was loaded on the beads, and beads
were incubated for 60 min at RT with overhead rotation. Beads were harvested by
centrifugation (5 min, 500 x g) and washed three times with 10 mL NPI-10 and once with
10 mL NPI-20 for 10 min each. Protein was eluted in 5 elution steps with 5 mL NPI-250
each. Fractions were pooled, concentrated over a 30 kDa cut-off Amicon ultrafiltration
device and buffer was exchanged on that same device by washing four times with PBS.
3.2.4.2 Purification of recombinant His-tagged GFP variants from P. pastoris
supernatants
For GFP proteins, filtered supernatants were concentrated with 10 kDa cut-off Amicon
ultrafiltration devices and washed within one device 3 times with NP buffer. Batch
purification with Ni-NTA beads was then carried out as described for β-galactosidase
in the previous paragraph, except that pooled elution fractions were concentrated to
2 mL with a 10 kDa cut-off Amicon ultrafiltration device and no buffer exchange was
performed. Instead, the 2 mL were loaded at 2 mL/min onto a PBS-equilibrated size
exclusion column packed with Sephacryl S200 HR with a Bio-Rad Biologic LP system.
2 mL fractions were collected and GFP containing fractions (determined by A280 and
optically by the greenish-yellowish GFP color) were pooled, concentrated and washed 3
times with PBS, using a 10 kDa cut-off Amicon ultrafiltration device.
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3.2.4.3 Purification of recombinant His-tagged GFP variants from HEK293T cell
supernatants
GFP containing OptiMem-supernatants from transfected HEK293T cells was purified
via Ni-NTA agarose like the recombinant GFPs from P. pastoris, except that elution
fractions were pooled and directly concentrated and washed three times with PBS, using
a 10 kDa cut-off Amicon ultrafiltration device without additional size exclusion chro-
matography.
3.2.4.4 Purification of MR-Fc chimeric proteins from HEK293T cell supernatants
Supernatants from HEK cells transfected with MR-Fc chimeras were purified by affinity
chromatography over pre-packed 1 mL Protein G columns according to the manufac-
turer’s manual. In short, the column was attached to the Bio-Rad BioLogicLP device,
and a flow of 1 mL/min was used in all steps. The column was equilibrated with Pro-
tein G binding buffer until A280 and conductivity baselines were constant. Supernatants
were diluted in double the volume Protein G binding buffer before loading. After load-
ing, the column was washed with Protein G binding buffer until baselines were constant.
Proteins were eluted with Protein G elution buffer. 970 µL fractions were collected in
1.5 µL reaction tubes, pre-filled with 30 µL Protein G neutralization buffer. Tubes were
directly inverted for mixing when fractions were collected. Fractions containing the main
protein according to A280 were pooled and transferred to a 50 kDa cut-off Amicon ul-
trafiltration unit. Samples were concentrated and washed 4 times with PBS to get rid
of contaminating salts.
3.2.4.5 Purification of recombinant His-tagged β-galactosidase from E. coli
pellets
Protein purification was mainly done according to the guidelines for denatured protein
from the Protino Ni-NTA Agarose manual (Macherey-Nagel) with some modifications.
The weight of the pellets was determined, and pellets were resuspended thoroughly
in 2 mL/g DNPI-10 supplemented with protease inhibitors without EDTA and 1 mm
PMSF. Pellets were lysed on ice by sonication (1 min constant pulse with 40 % am-
plitude, followed by 10 min 3x pulse with 40 % amplitude), and lysates were cleared
by centrifugation (20,000 x g, 30 min, 4 ◦C). Lysates were filtered through a 0.45µm
cellulose acetate filter, and batch purification was performed with Ni-NTA agarose as
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described for P. pastoris-derived proteins, except that all NP-buffers were exchanged by
DNP-buffers containing 8m urea as a denaturing agent. Elution fractions were pooled,
and a 30 kDa cut-off Amicon ultrafiltration unit was used to concentrate and wash the
protein five times with PBS to dilute the urea to submillimolar concentrations.
3.2.5 Protein modification
3.2.5.1 Enzymatic deglycosylation with Endo H or PNGase F
Proteins were enzymatically deglycosylated by treatment with Endo H or PNGase F.
Endo H treatment was exclusively performed under native conditions. 1–5 mg of target
protein were typically supplemented with 100U enzyme per mg protein in 1x GlycoBuffer
3 (NEB) and incubated for 18 h at 37 ◦C. PNGase F treatment of OVA-647 intended for
uptake experiments was also performed under native conditions with 5U Enzyme per
20 µg Protein in 1x GlycoBuffer 2 (NEB) for 6 days at 37 ◦C. The PNGase F treatment of
proteins intended for western blot analysis or ELISA-like binding assays was performed
under denaturing conditions according to the manufacturer’s manual.
3.2.5.2 Labeling of β-galactosidase with Alexa Fluor 647
The labeling of 100µg β-galactosidase was performed with the Molecular Probes Alexa
Fluor Antibody Labeling Kit according to the manufacturer’s manual. Labeling effi-
ciency was calculated as described in the manual and suggested 1–2 mol of dye per mol
protein. As an estimate, the molar extinction coefficient of unglycosylated β-galacto-
sidase was determined with the ProtParam online tool at the ExPASy Bioinformatics
Resource Portal (web.expasy.org/protparam/)[135] for this calculation.
3.2.5.3 Labeling of NST-GFP with DyLight 650
250 µg NST-GFP were labeled with the DyLight 650 NHS-ester labeling Kit (Thermo
Fisher Scientific) according to the manufacturer’s manual. The degree of labeling was
calculated according to the manual and suggested 4 mol dye per mol NST-GFP.
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3.2.6 Protein analysis
3.2.6.1 Determination of protein concentrations
Protein concentrations of purified proteins were determined by A280 absorbance, using
a Nanodrop 2000 UV/Vis specrometer. In cases of complex solutions like cell lysates,
a Bradford protein assay (Roti Quant, Carl Roth) or a bicinchoninic acid (BCA) assay
(Pierce BCA Protein Assay Kit, Thermo Fisher Scientific) was performed, as described
in the manufacturers’ manuals. Tests were chosen according to the best compatibility
with putative contaminants in the complex mixture, as recommended by Thermo Fisher
Scientific.
3.2.6.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
The separation of proteins according to their size was performed by discontinuous gel
electrophoresis as described by Laemmli [136] with a vertical mini gel electrophoresis
system from Bio-Rad. Stacking gels were prepared according to Table 3.3.
Table 3.3: Composition of stacking gels — recipe for 2 mL
Reagent Volume of components (mL)
Ultrapure H2O 1.4
30 % acryl-bisacrylamide mix 0.33
1.5m Tris (pH 6.8) 0.25
10 % (w/v) SDS 0.02
10 % (w/v) ammonium persulfate 0.02
TEMED 0.002
Polyacrylamide concentrations from 8–12 % were used according to the molecular
weight range at which separation was needed. Resolving gels were prepared accord-
ing to Table 3.4.
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Table 3.4: Composition of resolving gels — recipe for 10 mL
Volume of components mL
Reagent for 8 % for 10 % for 12 %
Ultrapure H2O 4.6 4.0 3.3
30 % acryl-bisacrylamide mix 2.7 3.3 4.0
1.5m Tris (pH 8.8) 2.5 2.5 2.5
10 % (w/v) SDS 0.1 0.1 0.1
10 % (w/v) ammonium persulfate 0.1 0.1 0.1
TEMED 0.006 0.004 0.004
Samples were denatured by supplementing them with 1x Laemmli buffer and boiling
for 5 min at 95 ◦C. Typically, 1 µg purified protein or 100–300 µg total protein from
cell lysates were loaded per lane. For comparative analysis during protein purification,
volumes of loaded aliquots were chosen to represent equal proportions of each fraction,
e.g. if 10µL of a 10 mL input fraction were loaded, a 5 mL elution fraction would be
potentially 2x concentrated and hence only 5µL were loaded. Electrophoresis was carried
out in 1x SDS buffer with 20 mA per gel.
3.2.6.3 Coomassie staining
For coomassie staining, SDS-gels were rinsed once in ultrapure H2O after gel elec-
trophoresis and then incubated on a rocker at RT for 2–18 h in Roti-Blue, diluted
in ultrapure H2O and supplemented with 20 % (v/v) MeOH. Afterwards, gels were
destained by incubation in ultrapure H2O for 2–18 h.
3.2.6.4 Western blot/far-western blot analysis
All western and far-western blot analyses were performed according to the semi-dry
method on nitrocellulose membranes. Briefly, gels, blotting paper, and nitrocellulose
membranes were incubated for 5 min in Towbin buffer and then assembled on the Bio-
Rad Trans-Blot SD Semi-Dry Transfer Cell according to the manufacturer’s manual.
Blotting was carried out at 25 V and 200 mA per mini gel for 45 min. Blots were blocked
in TBST + 5 % milk powder for 30 min at RT. Standard western blots were then in-
cubated with primary antibodies, diluted 1/1000 in TBST for 1 h at RT. Blots were
washed three times with TBST for 10 min and then incubated with the corresponding
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horseradish peroxidase (HRP)-conjugated secondary antibody diluted 1/5000 in TBST
for 1 h at RT. Finally, blots were washed again three times with TBST for 10 min. Far-
western blots were incubated with 50 µg/mL MR-CTLD in TBSTC for 18 h at 4 ◦C and
then washed three times with TBSTC for 10 min. Far-western blots were then incu-
bated with 1/5000 HRP-conjugated anti-human IgG secondary antibody in TBSTC for
1 h at RT and finally washed three times with TBSTC for 10 min. Blots were devel-
oped by adding ECL substrate, and chemiluminescence was detected with the Bio-Rad
ChemiDoc MP system.
3.2.6.5 Enzyme-linked immunosorbent assay (ELISA)
Transparent 96-well ELISA plates were coated with 0.5µg/mL capture antibody in 50µL
ELISA coating buffer for 1 h at 37 ◦C and then washed three times with 150µL ELISA
washing buffer. Wells were then blocked with 100µL ELISA blocking buffer for 30 min
at RT and afterwards washed again three times. 50 µL samples and the appropriate
standard serial dilution were added, and plates were incubated for 1 h at 37 ◦C, followed
by three washing steps. Captured proteins were detected by incubation with 0.5µg/mL
biotinylated capture antibody in 50µL ELISA blocking buffer for 1 h at 37 ◦C and then
washed three times. Wells were then incubated with 10µg/mL HRP-conjugated neutra-
vidin in PBS for 30 min at RT and afterwards washed again three times. HRP activity
was monitored by adding 50 µL 2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) solution (1 mg/mL ABTS in ABTS buffer, supplemented with 15 µL H2O2 per
10 mL solution) and measuring the absorbance at 405 nm.
3.2.6.6 Fc-chimeric ELISA-like binding assay
Assays were carried out as described previously [66], except that TBS was used instead
of PBS to prevent precipitation of insoluble calcium phosphate. In short, 96-well plates
were coated with 0.1 mg/mL of the protein substrate in Fc-chimeric coating buffer for
1 h at 37 ◦C. Plates were washed three times with 150µL TBST and blocked for 1 h with
TBST + 0.3 % BSA at RT. For assays including the MR-Nterm Fc-chimera, Fc-chimeric
proteins (10µg/mL) were pre-incubated for 1 h at RT with anti-human alkaline phos-
phatase (AP)-conjugate (1:100) in TBSTC + 0.3 % BSA. Plates were then incubated
with these immune complexes for 1 h at RT. After three washing steps with 150µL TB-
STC, plates were incubated with 1 mg/mL 4-Nitrophenyl phosphate in AP substrate
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buffer, and absorbance was monitored at 405 nm. For all downstream analyses without
MR-Nterm, the MR-CTLD Fc-chimeric protein and Fc control were not complexed as de-
scribed above. Instead, after 1 h incubation with uncomplexed Fc-chimeras (10 µg/mL)
in TBSTC, plates were washed three times with TBSTC and incubated with anti-human
AP (1:1000) for 1 h at RT. After another three washes with TBSTC, detection was per-
formed with the substrate as described above.
3.2.6.7 Fluorescence spectroscopy
For emission and excitation spectra, proteins were adjusted to 0.1 mg/mL in PBS, and
500 µL were placed in a 1 mL quartz cuvette. Spectra were collected with a FluoroMax-4
spectrofluorometer. Excitation spectra were collected from 340–520 nm with a band-
width of 10 nm, and fluorescence was detected at 540 nm with a bandwidth of 1 nm.
Emission spectra were detected from 500–750 nm with a bandwidth of 1 nm by constant
excitation at 488 nm with 5 nm bandwidth.
3.2.7 Cellular assays
3.2.7.1 Antigen uptake by BM-DCs
BM-DCs were harvested with 2 mm EDTA in PBS on day 7 or 8. 2× 105 BM-DCs
were seeded per well in a 24-well cell culture plate. Cells were incubated at 37 ◦C and
5 % CO2 for at least 45 min to allow the cells to attach to the plate bottom. If not
otherwise declared, cells were pulsed for 20 min with 250 ng/mL Alexa Fluor 647-labeled
ovalbumin (OVA-647), 500 ng/mL Alexa Fluor 647-labeled β-gal or 1 µg/mL GFP in
uptake medium at 37 ◦C and 5 % CO2. The blocking of the uptake was performed
by co-incubation with 3 mg/mL yeast mannan, 3 mg/mL unlabeled ovalbumin or by
adding 2.5 mm EDTA. Cells were harvested by scraping, transferred to FACS tubes and
washed once with 3 mL PBS. Finally, cells were resuspended in 250µL FACS buffer and
analyzed by flow cytometry with either a guava easyCyte (Millipore) or an LSR II (BD
Biosciences).
3.2.7.2 Subcellular localization of antigens and colocalization in BM-DCs
BM-DCs were harvested with 2 mm EDTA in PBS on day 7. 2× 105 BM-DCs were
seeded on glass coverslips that were placed in a 24-well cell culture plate. Cells were al-
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lowed to adhere for 30–60 min at 37 ◦C and 5 % CO2 and were then pulsed with 1 µg/mL
Alexa Fluor 647-labeled β-gal alone or in combination with 500 ng/mL Alexa Fluor 488-
labeled OVA or transferrin (Trf) for 20 min. In order to study NST-GFP localization,
cells were incubated with 500 ng/mL NST-GFP and 250 ng/mL OVA-647. Cells were
washed three times with PBS and fixed with fixation buffer for 15 min. Samples intended
for intracellular staining were then permeabilized and blocked in intracellular staining
buffer + 5 % BSA for 1 h and then stained with 1/200 anti-EEA1, 1/500 anti-LAMP-1
or 1/100 Alexa Fluor 488-conjugated anti-MR primary antibodies in staining buffer for
1 h. After washing three times with PBS, EEA1 and LAMP-1 stained cells were incu-
bated with 1/1000 Alexa Fluor 568-labeled anti-rabbit or anti-rat secondary antibodies,
respectively, in staining buffer for 30 min and washed again three times with PBS. All
samples were then stained with 1µg/mL DAPI in PBS for 10 min. Afterwards, sam-
ples were washed 4 times with PBS and once with ultrapure H2O and finally mounted
in Fluoromount onto microscope slides. Fluorescence microscopy was performed on an
AxioObserver inverse microscope with a ZEISS ApoTome system.
3.2.7.3 Antigen uptake by HEK293T cells expressing the MR
HEK293T cells expressing the MR (HEK-MR) or control cells (HEK) were harvested the
day before the experiment with Trypsin/EDTA solution, and 2× 105 cells were seeded
per well in a 24-well plate. 10 min before the experiment, 4 ◦C samples and Alexa Fluor
647-labeled β-gal solutions were put on ice in the fridge. 37 ◦C cells were then pulsed
with 500 µg/mL pre-warmed Alexa Fluor 647-labeled β-gal in HEK cell medium for 15
or 30 min at 37 ◦C. 4 ◦C cells were treated likewise with the pre-cooled antigen at 4 ◦C
on ice in the fridge. Cells were washed once with 1 mL ice-cold PBS. Supernatants were
aspirated, and cells were harvested in 250µL ice-cold fluorescence-activated cell sorting
(FACS) buffer and analyzed by flow cytometry on an LSR II.
3.2.7.4 Antigen uptake by PBMC-derived DCs and macrophages
4× 105 PBMC-derived DCs or macrophages were seeded per well in a 24-well plate.
Cells were incubated for at least 1 h before 1 µg/mL of NST-GFP, QST-GFP or Endo
H-treated NST-GFP were applied in the absence or presence of 3 mg/mL mannan for
20 min. Uptake was stopped by putting the cells on ice and adding 1 mL ice-cold PBS.
Cells were harvested by scraping, transferred to FACS tubes and collected by centrifuga-
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tion (300 x g, 5 min, 4 ◦C). Cells were washed once with FACS buffer, then resuspended
in FACS buffer and analyzed on an LSR II flow cytometer.
3.2.7.5 MR-surface expression of PBMC-derived DCs and macrophages
PBMC-derived DCs or macrophages were harvested in FACS buffer by scraping, and
4× 105 cells were transferred to FACS tubes and washed once with FACS buffer. Cells
were incubated with 1/1000 biotinylated anti-human CD206 in FACS buffer supple-
mented with 1 % (v/v) mouse serum for 20 min at 4 ◦C. Cells were harvested by cen-
trifugation (300 x g, 5 min, 4 ◦C), washed twice with FACS buffer and then incubated
with 1/1000 Alexa Fluor 647-conjugated streptavidin in FACS buffer for 20 min at 4 ◦C).
Cells were washed again with FACS buffer, resuspended in FACS buffer and analyzed
on an LSR II flow cytometer.
3.2.7.6 Acquisition of activation marker surface expression on BM-DCs after
stimulation
Day 3 BM-DCs were directly split on 3 cm dishes in order to minimize pre-activation of
BM-DCs due to additional harvesting at day 7. On day 6, 4µg/mL control-treated or
Endo H-treated β-gal from P. pastoris, 4µg/mL β-gal from E. coli or 1µg/mL LPS were
added and cells were incubated for another 18 h. The next day, cells were harvested
by scraping, collected by centrifugation (300 x g, 5 min, 4 ◦C) and washed once with
FACS buffer. Cells were then stained with 1/200 dilutions of fluorescently labeled anti-
CD40, anti-CD80, anti-CD86 or anti-MHC I in FACS buffer, supplemented with 1 %
(v/v) mouse serum for 20 min at 4 ◦C. Cells were washed again with FACS buffer and
analyzed on the guava easyCyte flow cytometer.
3.2.7.7 Detection of cytokine secretion by BM-DCs after stimulation
Day 7 BM-DCs were harvested with 2 mm EDTA in PBS, and 1× 105 cells were seeded
per well in a 96-well plate. Cells were stimulated with 100µg/mL control-treated or
Endo H-treated β-gal for 24 h. As controls, cells were incubated with 0.1µg/mL LPS or
without any further stimuli. Cells were centrifuged (300 x g, 5 min), and supernatants
were carefully transferred and analyzed for the presence of IL-6, IL-12 and TNF-α by
ELISA.
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3.2.7.8 Proliferation and IL-2 secretion of OT-I, OT-II and DesTCR cells after
stimulation
Day 7 BM-DCs were harvested with 2 mm EDTA in PBS, and 1× 105 cells were seeded
per well in a 96-well plate. Cells were incubated for 30 min before adding 20 µg/mL
untreated β-gal, Endo H-treated β-gal, 1 µg/mL LPS or medium only and incubating
for 1 h. After three washing steps with PBS, BM-DCs intended for presentation to
OT-I or OT-II cells were pulsed for 1 h with 125 nm OVA257–264 or 800 nm OVA323–339,
respectively. In the mean time splenocytes from OT-I, OT-II and DesTCR mice were
isolated. Mice were first anesthetized with isofluran and then euthanized by cervical
dislocation. Spleens were removed, passed through a metal cell strainer, and resuspended
thoroughly in PBS by pipetting to get a single cell suspension. This suspension was
further purified through a nylon sieve to remove rough debris. Cells were counted by
adding acetic acid (0.5 % (v/v)) and trypan blue to exclude erythrocytes and other dead
cells.
For the assessment of IL-2 secretion, BM-DCs were washed again with PBS and
then incubated with 1× 105 splenocytes for 18 h in T cell medium. Finally, cells were
centrifuged and supernatants were analyzed by ELISA for the presence of IL-2.
To analyze T cell proliferation, splenocytes were stained with 1 µm carboxyfluorescein
succinimidyl ester (CFSE) in PBS for 20 min at 37 ◦C. Staining was stopped by adding
ice-cold T cell medium, and cells were subsequently washed twice with PBS. The cell
number was determined again as described above. BM-DCs were then washed with
PBS, and 1× 105 cells were added in 100µL. After 24 h, 200µL fresh T cell medium
was added, and cells were incubated for another 48 h. After a total of 3 days co-culture,
T cells were harvested by centrifugation (500 x g, 7 min, 5 ◦C) and stained with 1/1000
PerCP/Cy5.5-conjugated anti-CD8 or anti-CD4 antibodies in 40µL FACS buffer for
20 min at 4 ◦C. Cells were washed with 200µL FACS buffer and resuspended on the
96-well plate in 50 µL FACS buffer. Cells were analyzed by flow cytometry with a HTS
plate reader system (BD Biosciences) on the LSR II. Analysis was performed by gating
on single cells that were positive for the respective surface marker and then measuring
the cell count of the individual CFSE dilution profile peaks. Expansion indices were
then calculated as previously described [137].
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3.2.8 In vivo experiments
Animal handling and immunizations were performed by Janina Ku¨pper (AG Schumak,
UK Bonn). C57BL/6J mice were immunized by subcutaneous injection into the left
inguinal area at day -13 and day -6 with 50µg glycosylated or deglycosylated β-gal
or NST-GFP-S8L supplemented with 50 ng LPS per injection. Na¨ıve mice received no
treatment.
3.2.8.1 In vivo cytotoxicity assay
On day -1 the assessment of in vivo cytotoxicity was mostly performed as previously
described [138]. In brief, C57BL/6J splenocytes were isolated as described above. Target
cells were pulsed with the β-gal497–504, β-gal96–103 or OVA257–264 peptide (2 µm) in PBS
for 25 min at 37 ◦C, control cells were incubated in PBS only. Target cells were then
stained with 1.5µm CFSE, whereas control cells were stained with 0.15 µm CFSE for
another 25 min at 37 ◦C. Staining was stopped by adding ice-cold T cell medium, and
cells were washed twice with ice-cold PBS. Staining was controlled by flow cytometry
on a BD FACSCantoTM II (BD Bioscience). Cells were then pelleted by centrifugation
and adjusted to 5× 107 cells per mL in 0.9 % NaCl, and the three groups of mice (na¨ıve,
untreated glycoprotein, Endo H-treated glycoportein) were injected intravenously with
a mixture of 5× 106 control cells and 5× 106 target cells. After another 18 h (day 0),
animals were anesthetized with isofluran and then euthanized by cervical dislocation.
Inguinal lymph nodes were isolated, perfused with 0.05 % collagenase, cut in small pieces
and incubated for 30 min at 37 ◦C. Cells were washed, resuspended in MACS buffer
and filtered through a nylon sieve before being analyzed by flow cytometry on a BD
FACSCantoTM II (BD Bioscience). Specific killing was calculated with the formula:
% specific kill = 100−
(
target cells
control cells
)
sample(
target cells
control cells
)
na¨ıve group mean
× 100
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3.2.8.2 Ex vivo restimulation and IFN-γ ELISA
To determine the secretion of IFN-γ, cells from draining lymph nodes isolated as de-
scribed above were resuspended in T cell medium, and 1× 106 cells were seeded per well
in a 96-well plate. Cells were re-stimulated with 2µm of β-gal497–504 peptide overnight at
37 ◦C. The next day, cells were centrifuged, and IFN-γ concentration in the supernatant
was determined by ELISA.
3.2.8.3 Ex vivo determination of antigen-specific antibodies
Before euthanasia, blood was taken from animals immunized as described above. The
blood was allowed to clot and sera were collected by centrifugation (2000 x g, 10 min).
Control-treated or Endo H-treated β-gal (25µg/mL) were coated to an ELISA plate at
4 ◦C for 18 h. Afterwards, plates were washed three times with PBST. Samples were
then incubated with serum (diluted 1/64 in PBS) for 2 h and detected with 1/1000
HRP-conjugated whole mouse IgG-specific antibody in PBS by the standard ELISA
procedure.
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4.1 The binding of ovalbumin to the mannose receptor
is mediated by N-linked glycans
The C-type lectin-like domains (CTLDs) of the MR are essential for binding to OVA,
which was demonstrated by several studies inhibiting its C-type lectin activity [139, 140].
These studies rely either on competitive inhibition with C-type lectin ligands such as
yeast mannan, or on the absence or active removal of calcium ions, which are essential
for the CTLDs to fulfill their sugar-binding activity [62, 141]. Though all these data
indicate that the glycoprotein OVA has to bind via its glycan to the CTLDs of the MR,
a direct proof is still missing.
To directly address the issue of glycan-dependency we used human IgG1 Fc-chimeric
proteins of MR-subunits, which have been successfully applied to investigate the binding
specificities of MR-subdomains to different ligands in vitro [66]. The chimeric proteins
either comprise the N-terminal portion of the MR (MR-Nterm) consisting of the CR, the
FNII domain and the first two carbohydrate recognition domains, or the C-type lectin
activity-bearing C-terminal domain (MR-CTLD) comprising the CRDs 4–7 (Figure 2.4).
As a control, the human Fc fragment was used to exclude binding artifacts of the fused
IgG1 Fc region.
In an ELISA-like assay the MR-CTLD clearly bound to immobilized ovalbumin (Fig-
ure 4.1 A), whereas MR-Nterm bound to collagen as previously described [66]. BSA
served as a negative control and was bound by neither of the detecting proteins. To
investigate whether the binding of the MR-CTLD to OVA is really mediated by an N-
glycan, OVA was treated with the glycosidase PNGase F. Indeed, binding of MR-CTLD
was lost after the deglycosylation of OVA (Figure 4.1 A).
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We also used the MR-CTLD protein in a far-western blot analysis of deglycosylated
and control-treated OVA, thereby confirming the binding of the MR-CTLD to glyco-
sylated OVA (Figure 4.1 B) and excluding binding artifacts to contaminating proteins,
which occur in commercial OVA preparations [72].
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Figure 4.1: Glycan-dependent binding and uptake of OVA by the mannose recep-
tor
(A) Binding of MR-CTLD, MR-Nterm Fc-chimeric proteins or isotype control
to immobilized OVA, PNGase F-treated OVA, collagen or BSA was determined
by ELISA. The graph depicts the mean of three replicates. Error bars indicate
standard error of the mean (SEM). (B) OVA or PNGase F-treated OVA were
separated by SDS-PAGE and detected by coomassie staining or far-western blot
with MR-CTLD. (C) Wildtype or MR-deficient BM-DCs were pulsed for 15 min
with Alexa Fluor 647 OVA conjugate, which was either control-treated or PN-
Gase F-treated. Fluorescence intensity was monitored by flow-cytometry. (D)
Wildtype or MR-deficient BM-DCs were pulsed for 15 min with low (0.25 µg/mL)
or high (4 µg/mL) concentrations of Alexa 647-conjugated transferrin (Trf). All
graphs show representative data of at least three independent experiments.
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Finally, we pulsed bone marrow-derived dendritic cells (BM-DCs), generated either
from wild-type (MR+/+) or mannose receptor-deficient mice (MR-/-), for 20 min with
deglycosylated or control-treated OVA and monitored the uptake by flow cytometry.
OVA uptake was markedly reduced after deglycosylation to a level comparable to MR-/-
BM-DCs (Figure 4.1 C), which exhibit strongly impaired OVA-uptake, as previously
described [51, 139]. Importantly, MR-/- BM-DCs are as competent in MR-independent
endocytosis as wild-type cells, demonstrated by the uptake of fluorescently labeled trans-
ferrin (Trf) (Figure 4.1 D).
These experiments not only verify that the binding and internalization of OVA by the
MR depends on the C-type lectin domains of the MR, but also show for the first time
that it is indeed solely attributed to the N-glycans on OVA.
4.2 Pichia pastoris glycosylates N-glycosylation motifs
incidentally present in non-glycoproteins and
thereby generates mannose receptor ligands
Lam et al. have previously expressed a part of ovalbumin (AA230–359) comprising
the glycosylation sites N292 and N311 in P. pastoris [120]. In a follow-up study they
showed that this recombinant protein was taken up by MR-expressing chinese hamster
ovary (CHO) cells but uptake was strongly reduced if both asparagines were substituted
by glutamines or upon blocking with yeast mannan [122]. Together with our data from
the deglycosylation experiments of hen ovalbumin this strongly suggests that P. pastoris
not only glycosylates the glycoprotein ovalbumin at its designated N-glycosylation sites,
but also adds N-glycans which are similar to OVAs natural N-glycans and hence are
ligands of the MR.
We followed up these findings and wanted to investigate whether we could use P. pas-
toris-derived N-glycosylation as a general MR-targeting strategy for proteins that are
non-glycosylated in their native state (e.g. cytosolic proteins). To this end, we chose a
portion (V10–L731) of the cytosolic E. coli protein β-galactosidase (β-gal) as a model
antigen. Though not glycosylated in its native state in E. coli, β-gal incidentally com-
prises five N-X-S/T motifs which could act as potential N-glycosylation sites (Figure 4.2
A). Four of these motifs are present in β-gal(V10–L731) (Figure 4.2 B).
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Figure 4.2: The model antigen β-galactosidase with its putative N-glycosylation
sites
(A) 3D structure of whole β-gal (PDB 1JZ7 [142]) with secondary structures
visualized as cartoons. α-helices in blue, β-sheets in yellow, loops and undefined
structures in green. The 5 asparagines within N-X-S/T motifs are visualized as
spheres. (B) Schematic overview of recombinant β-gal(V10–L731) as expressed
in P. pastoris. MF = mating factor alpha prepro leader sequence.
A protein has to enter the endoplasmic reticulum (ER) to get N-glycosylated [91].
Hence, N-terminal FLAG-tagged β-gal(V10–L731) was subcloned into the methanol in-
ducible yeast expression vector pPICZα, which contains the mating factor alpha prepro
leader sequence for secretion and a C-terminal 6xHis-tag for purification by immobilized
metal affinity chromatography (IMAC) (Figure 4.2 B). Assuming correct processing (i.e.
cleavage of the proteases Kex2 and Ste3 at the corresponding cleavage sites after the
leader sequence) the calculated molecular weight of the final protein without any post-
translational modifications is 87.9 kDa.
P. pastoris KM71H cells were stably transformed with this expression plasmid, and
protein expression was monitored during methanol induction for 120 h in yeast pellets
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and supernatants by SDS-PAGE and subsequent commassie staining or western blot
analysis against the FLAG- and the 6xHis-tag. A roughly 90 kDa protein, which was
positive for the FLAG- and the 6xHis-tag, was detected after 48 h in the supernatant
of β-gal(V10–L731)-transformed but not control-transformed (pPICZα backbone) yeast
cells (Figure 4.3). Analysis of yeast pellets revealed that expression started after 24 h
with protein species of a slightly higher apparent molecular weight (Figure 4.3). For
subsequent large-scale productions, induction was carried out for 72–96 h to reduce the
risk of the autolysis of yeast cells and proteolysis of the target protein after prolonged
incubation in buffer only.
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Figure 4.3: Expression and secretion of recombinant β-gal(V10–L731) after stable
transformation into P. pastoris KM71H
P. pastoris KM71H was stably transformed with recombinant β-gal(V10–L731),
as depicted in Figure 4.2 B. Proteinexpression in yeast pellets (P) and secretion in
the supernatant (S) during MeOH induction was monitored every 24 h for 120 h
and visualized by SDS-PAGE and subsequent coomassie staining or western blot
against the 6xHis- and the FLAG-tag.
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Figure 4.4: Immobilized metal affinity chromatography of recombinant β-gal(V10–
L731) via Ni-NTA resin
Concentrated supernatants (Input) were loaded for 1 h on Ni-NTA resin. Flow-
through was kept for analysis, and resin was extensively washed (wash 1–4).
Bound protein was eluted in 5 steps, and eluted fractions were pooled. Aliquots of
each fraction were separated by SDS-PAGE and visualized by coomassie staining
or western blot against the His-tag.
Supernatants of large scale cultures were concentrated for purification by ultrafil-
tration, and buffer was exchanged before His-tagged proteins were further purified by
IMAC. Visualization of the different fractions during IMAC by western blot revealed
that nearly all His-tagged proteins bound to the resin (i.e. no signal was found in the
flow-through fraction) and eluted readily within the first three elution steps (Figure 4.4).
The elution fractions were pooled, and buffer was exchanged against PBS to get rid of
the eluting reagent imidazole for further analysis.
We were then interested in finding out whether any domain of the MR could bind
to this secreted β-gal(V10–L731), which for convenience will from now on be referred
to as β-gal. To answer this question, the ELISA with MR-CTLD and MR-Nterm Fc-
chimeras was performed on immobilized purified protein. Binding could be detected for
MR-CTLD but not for MR-Nterm or the Fc control (Figure 4.5 A).
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Figure 4.5: MR-CTLD binds to recombinant β-gal from P. pastoris in a C-type-
lectin- and glycan-dependent manner
(A) The binding of MR-CTLD and MR-Nterm Fc-chimeric proteins or isotype
control (Control) to immobilized recombinant β-gal, OVA, collagen or BSA de-
termined by ELISA. (B) The binding of MR-CTLD to recombinant β-gal, OVA
or BSA in the absence or presence of 3 mg/mL mannan determined by ELISA.
Control = isotype control. (C) The binding of MR-CTLD to recombinant β-gal,
OVA or BSA in the presence or absence of calcium ions determined by ELISA.
Control = isotype control. (D) The binding of MR-CTLD, isotype control or
FLAG-antibody to control- or PNGase F-treated β-gal, determined by ELISA.
(E) Recombinant β-gal, purified from P. pastoris or E. coli, was treated with PN-
Gase F, Endo H or control-treated. Samples were analyzed by SDS-PAGE and
subsequent coomassie staining, western blot against the His-tag or far-western
blot with MR-CTLD. All graphs depict the mean values of three replicates and
are representative data of three independent experiments. Error bars indicate
SEM.
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Importantly, the binding of MR-CTLD to β-gal was inhibited by the competitive
MR-CTLD inhibitor mannan or in the absence of calcium ions, just like the binding to
ovalbumin (Figure 4.5 B, C). This points out that β-gal binding required the MR C-type
lectin activity, which in turn suggests the presence of glycosylation on β-gal. Strikingly,
the binding of MR-CTLD was abolished upon the deglycosylation of β-gal with PNGase
F, whereas deglycosylation had no influence on the recognition of the FLAG-tag on that
protein (Figure 4.5 D).
Next, purified β-gal, either secreted from P. pastoris or purified from E. coli lysates,
was deglycsoylated with either glycosidase, PNGase F or Endo H. Proteins were then
separated by SDS-PAGE and analyzed by coomassie staining, western blot against the
His-tag and far-western blot using MR-CTLD. MR-CTLD bound P. pastoris- but not
E. coli-derived β-gal and, in accordance with the results from the ELISA-like binding
assay, this binding was sensitive to glycosidase treatment with PNGase F or Endo H
(Figure 4.5 E).
These data demonstrate that incidentally occuring N-X-S/T motifs in cytosolic pro-
teins are N-glycosylated by P. pastoris and, importantly, that the attached glycans are
ligands of the MR C-type-lectin part, the same domain that also accounts for the binding
of OVA.
4.3 Pichia pastoris-derived β-galactosidase is
internalized by the mannose receptor
Since the binding of OVA to the MR leads to receptor mediated endocytosis of OVA
[51, 125], we investigated if the same holds true for P. pastoris-derived β-gal. For this
purpose, HEK293T cells expressing the MR (HEK-MR) or HEK293T control cells (HEK)
[125] were pulsed with fluorescently labeled β-gal (Figure 4.6). At 4 ◦C increased binding
of β-gal to HEK-MR cells was already detected as indicated by an increase in the mean
fluorescence intensity in comparison to HEK control cells. Upon incubation at 37 ◦C,
HEK cells expressing the MR actively took up the fluorescently labeled β-gal, as indicated
by increasing fluorescence over time, whereas HEK cells lacking the MR did not show
such distinct uptake.
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Figure 4.6: Uptake of fluorescently labeled β-gal by MR-expressing HEK293T cells
MR-expressing HEK293T cells (HEK-MR) or control HEK293T cells (HEK) were
pulsed with Alexa Fluor 647-conjugated β-gal at 37 ◦C or 4 ◦C for 15 or 30 min.
Fluorescence intensities were measured by flow cytometry, and arithmetic mean
fluorescence intensities (MFIs) were calculated. The graph shows the mean MFI
of three replicates. Error bars indicate SEM. The graph is representative for three
independent experiments. The histograms show one representative replicate of
the 15 min samples depicted in the graph.
Next we investigated the uptake of P. pastoris-derived β-gal by wild-type (MR+/+)
or MR-deficient BM-DCs (MR-/-). To this end, we first pulsed BM-DCs with increasing
concentrations of fluorescently labeled β-gal for 20 min and monitored β-gal uptake by
flow cytometry. MR-sufficient BM-DCs were superior in β-gal uptake to MR-deficient
BM-DCs at all concentrations tested (Figure 4.7 A), indicating that the MR plays a
dominant role in the uptake of glycosylated β-gal by BM-DCs. Pulsing BM-DCs with
constant β-gal amounts for different lengths of time further revealed that β-gal accumula-
tion by the MR even increased over time (Figure 4.7 B). This demonstrates the benefit
of targeting a recycling receptor like the MR [74] to specifically accumulate proteins
in target cells, even at low concentrations. The impact of MR-mediated β-gal uptake
was also investigated by fluorescence microscopy, which not only confirmed that MR-
sufficient cells accumulated more β-gal than their MR-deficient counterparts, but also
showed that the fluorescence is located in punctual subcellular compartments (Figure 4.7
C).
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Figure 4.7: Uptake of fluorescently labeled β-gal by BM-DCs
(A, B) Wildtype (MR+/+) or MR-deficient BM-DCs (MR-/-) were pulsed with
different concentrations of Alexa Fluor 647-conjugated β-gal for 20 min (A) or
with 500 ng/mL Alexa Fluor 647-conjugated β-gal for different time period (B).
Fluorescence intensities were measured by flow cytometry and arithmetic MFIs
were calculated. Graphs show the mean ± SEM MFI of three replicates and are
representatives of three independent experiments. Histograms show one repre-
sentative replicate of the last data points depicted in the graphs. (C) Wildtype
or MR-deficient BM-DCs were pulsed with 1 µg/mL Alexa Fluor 647-conjugated
β-gal for 20 min. Nuclei were stained with DAPI and cells were analyzed by
fluorescence microscopy. White bars indicate 20 µm.
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To investigate whether this MR-mediated β-gal uptake depended on the C-type lectin-
activity, we again pulsed BM-DCs with fluorescently labeled β-gal but this time co-
administered excess amounts of established MR ligands (i.e. yeast mannan or unlabeled
OVA) or the calcium chelating molecule EDTA and measured uptake by flow cytome-
try. In accordance with the findings on the isolated MR-CTLD, both the competitive
inhibition and the withdrawal of calcium ions abolished MR-mediated β-gal uptake com-
parable to the knock-out level (Figure 4.8 A). Likewise, the uptake of deglycosylated
β-gal was also reduced to knock-out level (Figure 4.8 B).
ȕ-­gal
%
  o
f  M
ax
MR +/+
MR -­/-­
ȕ-­gal
ȕ-­gal
Control +  mannan +  OVA +  EDTAA
ȕ-­gal
%
  o
f  M
ax
MR +/+
MR -­/-­
+  Endo  HControl
ȕ-­gal
ȕ-­gal
B
Figure 4.8: The uptake of fluorescently labeled β-gal by BM-DCs depends on the
C-type lectin activity of the MR and N-glycans on β-gal
(A) Wildtype (MR+/+) or MR-deficient BM-DCs (MR-/-) were pulsed for 20 min
with Alexa 647-conjugated β-gal either alone or in the presence of 3 mg/mL yeast
mannan, 3 mg/mL OVA, or in the presence of the calcium chelator EDTA. The
uptake of antigen was monitored by flow cytometry. (B) Cells as in (A) were
pulsed with control- or Endo H-treated fluorescently labeled β-gal. Uptake was
monitored by flow cytometry. Histograms show one representative replicate of at
least three independent experiments.
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These experiments prove that P. pastoris-derived β-gal is not only bound but also
subsequently internalized by the cell-associated full-length MR. Binding to the MR is
solely mediated by the interaction of its C-type lectin part with the P. pastoris-derived
N-glycan, confirming our previous findings with isolated MR subdomain-Fc chimeras.
Noteworthy, the attached N-glycans targeted the MR on BM-DCs very selectively, as
demonstrated by the low uptake of MR-/- cells.
4.4 Pichia pastoris-derived β-galactosidase is delivered
to early endosomal compartments
Endocytosed proteins typically enter the endolysosomal pathway for degradation. In
contrast to this, MR-endocytosed ovalbumin was shown to end up in an endosomal com-
partment positive for the MR, transferrin (Trf), the early endosome antigen-1 (EEA1)
but not the lysosomal-associated membrane protein 1 (LAMP-1), from where it was pro-
cessed for cross-presentation [51]. Hence, we were interested in the detailed subcellular
localization of endocytosed β-gal. To investigate this, we pulsed BM-DCs with differently
labeled β-gal and ovalbumin and analyzed the cells by fluorescence microscopy. Both
proteins ended up in the same compartments and importantly, β-gal positive compart-
ments were also positive for the MR, EEA1 and Trf, but not for the lysosomal marker
LAMP-1 (Figure 4.9). This suggests that P. pastoris-derived β-gal indeed ended up in
the same compartment that is related to cross-presentation of OVA.
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Figure 4.9: Fluorescently labeled β-gal ends up in compartments related to cross-
presentation after uptake by BM-DCs
Wildtype (MR+/+) BM-DCs were pulsed for 20 min with 1 µg/mL Alexa Fluor
647-conjugated β-gal and chased for another 20 min. Cells in the first panel were
simultaneously pulsed with 500 ng/mL Alexa Fluor 488-conjugated OVA or Trf.
Cells in the lower panels were stained for MR, EEA1 and LAMP-1. White bars
indicate 10 µm.
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4.5 Pichia pastoris glycosylates an artificial
N-glycosylation site, which can be used as a
mannose receptor-targeting strategy for proteins
lacking intrinsic N-X-S/T motifs
Since not all proteins incidentally bear N-X-S/T motifs like β-gal, a system was needed
to expand the MR-targeting strategy to all remaining non-glycoproteins. Hence, we
designed a P. pastoris expression plasmid (pPICZα-NST) which contains an N-terminal
N-X-S/T motif right between the mating factor alpha prepro leader sequence (MF)
for secretion and a multiple cloning site, followed by the His-tag for purification. We
optimized the glycosylation motif to guarantee a high degree of N-glycosylation. To this
end, the motif was initially placed N-terminally, because glycosylation site occupancy
was found to decrease from N- to the C-terminus [143]. Next, we preferred N-X-T to
N-X-S, as it has been shown that threonine is favored over serine at position 3 [143, 144],
and we chose the amino acid serine at position 2 (denoted as X in N-X-S/T), which gave
high N-glycosylation yield in a study investigating the X-position [145]. Finally, the tag
was flanked by glycine and methionine, which are structurally and chemically inert and
should thereby improve the sequon’s accessibility by the oligosaccharyltransferase [146].
To test this vector on a model protein, we chose enhanced green fluorescent protein
(GFP) [147–149]. Besides lacking intrinsic N-glycosylation motifs and having a free ac-
cessible N-terminus (Figure 4.10 A), this protein has already been successfully secreted
by P. pastoris [150] and is easily detectable in downstream assays by its intrinsic fluo-
rescence. The resulting modified GFP will henceforth be named NST-GFP (Figure 4.10
B). After transformation into P. pastoris KM71H, we made use of the intrinsic GFP flu-
orescence to develop a simple 96-well format semi-high throughput screen (see methods
section 3.2.3.4 for more details) to identify clones that show high secretion of NST-GFP
(Figure 4.10 C). Additionally, induced yeast pellets were also checked for remaining GFP
fluorescence and revealed that high secretion correlated with low residual fluorescence
in pellets (data not shown). This demonstrates the power of our screening method to
easily select clones with proper protein folding and secretion kinetics.
A high secreting clone was selected for large scale purification and NST-GFP was
readily detected during and after IMAC purification from P. pastoris supernatants by
its yellow color and green fluorescence (Figure 4.10 C).
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Figure 4.10: GFP as a model for proteins lacking intrinsic N-X-S/T motifs and its
purification from P. pastoris
(A) 3D structure of GFP (PDB 1GFL [151]) with secondary structures visu-
alized as cartoons. α-helices in red, β-sheets in yellow, loops and undefined
structures in green. N- and C-termini are illustrated in orange and blue, respec-
tively. (B) Scheme of GFP with the N-terminal glycosylation site (NST-GFP)
or control sequence (QST-GFP). MF = mating factor alpha prepro leader se-
quence. (C) Supernatants of n=96 NST-GFP or vector backbone transformed
P. pastoris clones were transferred to a 96-well plate after 48 h induction and
GFP fluorescence was detected. (D) Purified NST-GFP and β-gal at daylight
and after illumination with 470 nm.
Using the Fc-chimeric MR-proteins in an ELISA we first investigated if any part of
the MR bound to immobilized, purified NST-GFP. Indeed, MR-CTLD again recognized
the recombinant protein from P. pastoris, whereas MR-Nterm did not (Figure 4.11 A).
Furthermore, MR-CTLD binding to NST-GFP was inhibited by mannan (Figure 4.11
B) or the absence of calcium ions (Figure 4.11 C) just like MR-CTLD binding to OVA or
P. pastoris-derived β-gal. Concurrently, this binding was strongly reduced after degly-
cosylation with Endo H (Figure 4.11 D), suggesting that GFP was truly N-glycosylated
and MR-CTLD again recognized the P. pastoris-derived N-glycan.
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Figure 4.11: P. pastoris glycosylates the artificial N-X-S/T motif in NST-GFP re-
sulting in a C-type lectin- and glycan-dependent recognition by the
MR
(A) Binding of MR-CTLD, MR-Nterm or isotype control (Control) to immobi-
lized NST-GFP, OVA, collagen or BSA, determined by ELISA. (B) Binding of
MR-CTLD to NST-GFP, OVA or BSA in the absence or presence of 3 mg/mL
mannan, determined by ELISA. Control = isotype control. (C) As (B) but in
the presence or absence of calcium ions. (D) Binding of MR-CTLD, isotype con-
trol or His-tag antibody to control- or Endo H-treated NST-GFP, determined
by ELISA. (E) NST-GFP or QST-GFP purified from P. pastoris were PNGase
F-, Endo H- or control-treated. Samples were analyzed by SDS-PAGE and
subsequent coomassie staining, western blot against the His-tag or far-western
blot with MR-CTLD. All graphs depict the mean values of three replicates.
Error bars indicate SEM. The graphs are representative data of at least three
independent experiments.
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To verify that this N-glycosylation is due to the optimized N-X-S/T motif, we puri-
fied a control protein expressed by P. pastoris, where the asparagine in the motif was
exchanged by a glutamine (QST-GFP, Figure 4.10 B). SDS-PAGE of both proteins not
only revealed that QST-GFP has a lower apparent molecular weight, but also proved
that only NST-GFP is sensitive to deglycosylation by PNGase F or Endo H, whereas
QST-GFP is not (Figure 4.11 E). Concordantly, MR-CTLD only bound to NST-GFP
but not QST-GFP in a far-western blot analysis, and binding was lost after deglycosy-
lation of NST-GFP, confirming that MR-CTLD recognizes an N-glycan attached to the
artificial glycosylation site in NST-GFP.
Next, we investigated the uptake of NST-GFP by BM-DCs. To this end we pulsed
wild-type or MR-deficient BM-DCs with the antigen and monitored the GFP fluores-
cence by flow cytometry. Wild-type BM-DCs clearly took up more NST-GFP than
MR-deficient BM-DCs over a wide range of concentrations and incubation times (Fig-
ure 4.12 A). MR-mediated uptake could be blocked by yeast mannan and was strongly
reduced after deglycosylation of NST-GFP to the knock-out level (Figure 4.12 B). Ad-
ditionally, QST-GFP did not show such pronounced MR-dependent uptake (Figure 4.12
B), all together pointing to the necessity of the glycan-lectin interaction between NST-
GFP and the MR for the increased uptake of NST-GFP by wild-type BM-DCs. Equally
to β-gal, NST-GFP ended up in the same compartment as ovalbumin (Figure 4.12 C),
suggesting that the presented targeting strategy not only robustly targets the MR, but
also directs antigens reliably to compartments related to cross-presentation [51].
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Figure 4.12: BM-DCs take up NST-GFP by the MR in a C-type lectin- and glycan-
dependent manner
(A) Wild-type or MR-deficient BM-DCs were pulsed for 20 min with different
concentrations of NST-GFP, or with 1µg/mL NST-GFP for different period.
Protein uptake indicated by increase in GFP fluorescence was monitored by
flow cytometry. The graphs show the mean MFI ± SEM of three replicates and
are representatives of three independent experiments. The histograms show one
representative replicate of the last data points depicted in the graphs. (B) Wild-
type or MR-deficient BM-DCs were pulsed for 20 min with 1 µg/mL NST-GFP,
1 µg/mL NST-GFP + 3 mg/mL mannan, 1µg/mL Endo H-treated NST-GFP
or 1µg/mL QST-GFP. Protein uptake was monitored by flow cytometry. Rep-
resentative histograms of three independent experiments are shown. (C) Wild-
type BM-DCs were pulsed for 20 min with NST-GFP and Alexa 647-conjugated
OVA. The uptake of both proteins was visualized after 20 min chase by fluores-
cence microscopy. White bars indicate 10 µm.
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Although previous work on MR ligands [70] and the glycan composition of P. pastoris
(reviewed in [97]) strongly argues for a direct link between the attached glycan and
the MR-binding, we wondered whether P. pastoris-derived high-mannose gycosylation
is responsible for the success of our targeting strategy, or if any N-glycosylation is suffi-
cient for generating a MR ligand. HEK-derived N-glycans have been shown to contain
terminal fucose and to some extent GlcNAc and mannose [152], all of which can act as
MR ligands [68]. Hence, to answer our question, we expressed secreted NST-GFP and
QST-GFP variants in HEK293T cells (hNST-GFP and hQST-GFP, respectively).
The separation of HEK-derived hNST- and hQST-GFP by SDS-PAGE revealed that
hNST-GFP contained a protein species with higher apparent molecular weight com-
pared to hQST-GFP as visualized by coomassie staining and immunoblot (Figure 4.13
A). In contrast to hQST-GFP, hNST-GFP was also sensitive to PNGase F treatment
(Figure 4.13 A), strongly suggesting that hNST-GFP was truly N-glycosylated by HEK
cells. Nonetheless, MR-CTLD only bound to P. pastoris-derived and not to HEK-derived
NST-GFP in a far-western blot (Figure 4.13 A). Consistently, increased MR-dependent
uptake of NST-GFP by BM-DCs was only detected for the P. pastoris- but not the
HEK-derived protein (Figure 4.13 B).
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Figure 4.13: The MR-mediated binding and uptake of NST-GFP depend on the
attached N-glycans
(A) GFP variants were expressed in HEK293T cells (hNST-GFP, hQST-GFP).
P. pastoris-derived NST-GFP and HEK proteins were treated with PNGase F
and separated by SDS-PAGE. Proteins were visualized by coomassie staining
or western blot against the His-tag, and binding to MR-CTLD was determined
by far-western blot. (B) BM-DCs were pulsed for 20 min with different con-
centrations of P. pastoris-derived NST-GFP or HEK-derived hNST-GFP and
hQST-GFP. The uptake of the proteins was determined by monitoring the GFP-
fluorescence with a flow cytometer. The graphs depict the mean MFIs of three
replicates. Histograms show one representative replicate from each 1 µg/mL
samples.
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To investigate whether differences in mean fluorescence intensities detected by flow
cytometry are really due to different uptake and not to altered fluorescence properties,
excitation and emission spectra of all GFP variants were collected. Neither the source
of the protein (P. pastoris vs. HEK cells) nor the presence or absence of the N-glycans
had any influence on the wavelengths of excitation and emission maxima (Figure 4.14
A). Importantly, deglycosylation did not decrease the fluorescence intensity at 540 nm
after excitation at 488 nm (Figure 4.14 B), which would also explain lower fluoresence
signals during flow cytometry analysis.
In addition, one could argue, that GFP fluorescence is strongly pH dependent [153].
If MR-deficient BM-DCs shuttled GFP to a more acidic compartment than wild-type
BM-DCs, one could not distinguish whether the protein is less taken up, or whether fluo-
rescence simply vanishes directly after the uptake by MR-deficient BM-DCs. To test this
hypothesis, we pulsed wild-type or MR-deficient BM-DCs with NST-GFP conjugated to
DyLight 650 fluorophors, which are stable over a broad pH range (pH 4–9), and mon-
itored DyLight instead of GFP fluorescence. The uptake of DyLight-conjugated NST-
GFP by BM-DCs showed the same MR-dependency as observed for the GFP-fluorescence
(Figure 4.14 C), ruling out any effects of altered GFP fluorescence to account for our
observations.
Taken together, these data show that the optimized N-X-S/T motif can be used to
artificially glycosylate proteins which lack an intrinsic N-glycosylation site. The expres-
sion of such a protein in P. pastoris generated a MR ligand that behaved like the model
antigen OVA in both the binding and the uptake by the MR.
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Figure 4.14: Differences in uptake are not explained by altered fluorescence prop-
erties of GFP variants
(A) Normalized excitation and emission spectra of P. pastoris-derived (NST-
GFP, NST-GFP + Endo H, QST-GFP) or HEK-derived GFP variants (hNST-
GFP, hQST-GFP). Excitation spectra were monitored by emission at 540 nm.
Emission spectra were collected for excitation at 488 nm. (B) Emissionspectra
as in (A) without normalization. (C) Wild-type or MR-deficient BM-DCs were
pulsed for 20 min with DyLight 650-conjugated NST-GFP. Protein uptake was
monitored by flow cytometry. The graph shows mean DyLight 650 MFIs of
three replicates.
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Finally, we wanted to know if our targeting system might also be transferred to human
antigen presenting cells. To answer this question, we differentiated human PBMCs with
GM-CSF and IL-4 into dendritic cells (DCs) or with M-CSF into macrophages (MΦs).
We then pulsed these cells with NST-GFP or QST-GFP and investigated antigen uptake
by flow cytometry. Similar to the results with murine BM-DCs (Figure 4.12 B), there
was a strong increase in the uptake of NST-GFP in comparison to QST-GFP in human
DCs and a moderate increase in uptake by MΦs (Figure 4.15 A, left and right panel
respectively).
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Figure 4.15: P. pastoris-derived glycans target human peripheral blood mononu-
clear cell-derived DCs and MΦs
(A) Human PBMCs were differentiated with GM-CSF and IL-4 into DCs or
with M-CSF into MΦs. Cells were pulsed with NST-GFP, QST-GFP or Endo
H-treated NST-GFP in the absence or presence of mannan, and uptake was
monitored by flow cytometry. (B) Cells differentiated as in (A) were stained with
CD206 antibody, isotype control or left unstained. Staining was monitored by
flow cytometry. The graphs show the mean values of three biological replicates.
Error bars indicate SEM. The histograms show one representative sample of
each triplicate.
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NST-GFP uptake was reduced to QST-GFP uptake-level upon deglycosylation or by
addition of yeast mannan, suggesting a role of mannose-specific receptors in the enhanced
uptake of N-glycosylated NST-GFP (Figure 4.15 A). To check whether the MR (CD206)
could be one candidate for the lectin-dependent uptake of NST-GFP, we stained both
cell types for this receptor (Figure 4.15 B). Both cell types are positive for the MR,
and surface expression of the MR seems to correlate with the uptake of NST-GFP since
DCs not only take up more NST-GFP than MΦs, but are also more positive for the MR
(Figure 4.15 A, B).
This data clearly shows that enforced N-glycosylation by P. pastoris can serve as a
targeting strategy for human antigen presenting cells and suggests that the MR is one
possible target on these cells.
4.6 Enforced N-glycosylated proteins from Pichia
pastoris do not exhibit immunostimulatory effects in
vitro
Foreign glycosylation patterns can trigger signalling via pattern recognition receptors
[154, 155]. Hence, the question arises whether the artificial N-glycosyltion has an im-
munostimulatory effect on dendritic cells. To answer this question, we pulsed BM-DCs
with N-glycosylated or deglycosylated β-gal and monitored the secretion of cytokines.
Whereas the TLR-4 ligand lipopolysaccharide (LPS) stimulated secretion of IL-6, IL-12
and TNF-α, none of these cytokines was released after 24 h upon treatment with either
glycosylated or deglycosylated β-gal (Figure 4.16 A). Similarly, treatment of BM-DCs
with LPS strongly increased the surface expression of the activation markers CD40,
CD80, CD86 and MHC class I molecules, whereas P. pastoris-derived β-gal did hardly
affect surface expression in either its glycosylated or its deglycosylated form (Figure 4.16
B). Noteworthy, E. coli-derived β-gal enhanced surface expression similar to pure LPS
(Figure 4.16 B).
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Figure 4.16: P. pastoris-derived N-glycans do not activate BM-DCs
(A) BM-DCs were pulsed with medium (control), β-gal, Endo H-treated β-
gal or LPS. Cytokine secretion after 18 h was analyzed by ELISA. ND = not
detectable. (B) BM-DCs were pulsed with medium (control), β-gal, Endo H-
treated β-gal, E. coli-derived β-gal or LPS. After 18 h, surface expression of the
indicated activation markers was analyzed by flow cytometry, and MFIs were
calculated. All graphs show the mean values of three replicates. Error bars
depict SEM.
To fully assess the immunostimulatory impact of P. pastoris derived N-glycosylation
in the context of antigen presentation, we pre-treated BM-DCs with glycosylated or de-
glycosylated β-gal and investigated their capacity to present the OVA-derived epitopes
OVA257–264 or OVA323–339 to OVA-specific CD8+ (OT-I) or CD4+ (OT-II) T cells, respec-
tively (Figure 4.17 A, B). Concordantly detected by IL-2 secretion and lymphoprolifer-
ation, CD8+ and CD4+ T cell activation was both increased after BM-DC stimulation
with LPS but not β-gal, irrespective of the proteins glycosylation state.
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We also investigated the presentation of endogenous peptides by BM-DCs to DesTCR
T cells. These are transgenic T cells with a H-2Kk haplotype that recognize three
endogenous peptides on H-2Kb expressed by C57BL/6J BM-DCs in an alloreaction [126,
156, 157]. Similar to the presentation of exogenous antigens on MHC I to OT-I cells,
the presentation of endogenous peptides to DesTCR T cells was not altered by pre-
stimulation with P. pastoris-derived β-gal (Figure 4.17 C).
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Figure 4.17: The mere presence of P. pastoris-derived N-glycans has no effect on
antigen presentation
(A) BM-DCs were pre-stimulated with β-gal, Endo H-treated β-gal or LPS and
pulsed with the MHC I-restricted OVA-peptide OVA257–264. Cells were either
co-cultured with OVA-specific CD8+ T cells (OT-I) and IL-2 secretion after 18 h
was determined by ELISA (upper panel), or cells were co-cultured with fluores-
cently labeled OT-I T cells, and proliferation was determined after 3 days by
flow cytometry (lower panel). (B) Experimental procedure as in (A), except
that BM-DCs were pulsed with the MHC II-restricted peptide OVA323–339 and
co-cultured with OVA-specific CD4+ T cells (OT-II). (C) Experimental proce-
dure as in (A) except that no exogenous peptide was pulsed, negative control
was without BM-DCs and co-culturing was done with DesTCR T cells. ND =
not detectable. All graphs show the mean values of three replicates and are
representative for three independent experiments. Error bars depict SEM.
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The presented data strongly suggest that P. pastoris-derived N-glycosylation has no
impact on DC maturation and subsequent T cell activation per se.
4.7 Pichia pastoris-derived N-glycans evoke converse
cytotoxic activities for different antigens and are not
beneficial for a humoral response in vivo
As described in the introduction, P. pastoris was already used in different in vivo exper-
iments as an expression system for glycoproteins in vaccination approaches. However,
these studies neither used enforced N-glycosylation on non-glycoproteins, nor did they
compare the immunogenicity of glycosylated vs. glycosidase-treated proteins. Hence,
the effects of P. pastoris-derived N-glycans in vivo remained elusive.
We addressed this open question by performing in vivo immunization trials with gly-
cosylated or Endo H-treated β-gal (Figure 4.18 A). Each protein was injected subcuta-
neously into recipient mice as depicted in Figure 4.18 B. To investigate the influence
of such a vaccination strategy on cytotoxic CD8+ T cell activity, we intravenously in-
jected a 1:1 mixture of differentially labeled splenocytes, either pulsed with the β-gal
specific epitope ICPMYARV (target cells) or medium only (non-target cells), into the
tail vein of the recipients. After 18 h, draining lymph nodes were isolated and analyzed
for the presence of target and non-target cells by flow cytometry. Analysis revealed a
specific elimination of target cells after immunization with glycosylated β-gal, which was
markedly — though not significantly — reduced in the group vaccinated with deglyco-
sylated β-gal (Figure 4.18 C). Concordantly, re-stimulated lymph node cells from mice
immunized with glycosylated β-gal showed robust IFN-γ secretion after 24 h, which was
decreased in the group immunized with deglycosylated β-gal (Figure 4.18 D).
To investigate whether this increase in cytotoxicity is a general feature of P. pastoris-
derived N-gylcans, we fused the OVA epitope SIINFEKL (S8L) to NST-GFP (NST-
GFP-S8L) and immunized mice with glycosylated or Endo H-treated NST-GFP-S8L,
as depicted in Figure 4.18 B. To our surprise, cytotoxicity against NST-GFP-S8L was
significantly increased after deglycosylation (Figure 4.18 E), which is contrary to the
effect of N-glycans on β-gal. Since both proteins showed a similar N-glycan-dependent
capacity to ligate the C-type lectin domain of the MR, it was anticipated that N-glycans
will have similar effects on the in vivo cytotoxicity of both proteins.
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Instead, this result suggests that the effect of P. pastoris-derived N-glycans on a
cytotoxic response in vivo depends on the nature of the antigen.
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Figure 4.18: Converse in vivo cytotoxicity after deglycosylation of β-gal and NST-
GFP-S8L
(A) β-gal was purified as before, Endo H- or control-treated and further pu-
rified by ultrafiltration. Proteins were separated by SDS-PAGE and analyzed
by coomassie staining, western blot against the His-tag or far-western blot with
MR-CTLD. (B) Immunization scheme. s.c. = subcutaneous, i.v. = intravenous,
LN = lymph node. (C) Recipient mice (n = 28) were immunized according to
the scheme in (B) with Endo H- or control-treated β-gal depicted in (A). Drain-
ing lymph nodes were isolated, and β-gal-related cytotoxicity was determined
by measuring the specific elimination of β-gal497–504 (ICPMYARV)-pulsed tar-
get cells by flow cytometry. (D) Isolated lymph node cells from n = 12 mice
treated as in (B) were re-stimulated with β-gal497–504 (ICPMYARV), and IFN-γ
was detected after 18 h by ELISA. (E) Recipient mice (n = 6) were immunized
according to the scheme in (B) with Endo H- or control-treated NST-GFP-S8L.
Draining lymph nodes were isolated, and cytotoxicity was determined by mea-
suring the specific elimination of OVA257–264 (SIINFEKL, S8L)-pulsed target
cells by flow cytometry. Error bars depict SEM. P-values were calculated by
ANOVA and Tukey HSD post hoc analysis.
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Next, we were interested in the question how enforced N-glycosylation would effect
CD4+ T cell activity. To this end, we measured the humoral response in the sera of the
same mice as in Figure 4.18 C and E by detecting whole IgG specific for glycosylated or
deglycosylated β-gal or NST-GFP-S8L (Figure 4.19 A, B).
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Figure 4.19: Increased humoral immune response after the removal of P. pastoris-
derived N-glycans
(A) Serum from recipient mice (n = 28) depicted in Figure 4.18 C was analyzed
for the presence of IgG antibodies specific for β-gal (left panel) or Endo H-
treated β-gal (right panel) by ELISA. Vaccination groups are indicated on the
x-axis: Na¨ıve group = grey bars, β-gal group = black bars, Endo H-treated
β-gal group = white bars. (B) Serum of NST-GFP-S8L immunized mice (n =
6) depicted in Figure 4.18 E was collected and analyzed for the presence of IgG
antibodies specific for NST-GFP-S8L (left panel) or Endo H-treated NST-GFP-
S8L (right panel) by ELISA. Vaccination groups are indicated on the x-axis:
Na¨ıve group = grey bars, NST-GFP-S8L group = black bars, Endo H-treated
NST-GFP-S8L group = white bars. Whole IgG was determined as fold response
of na¨ıve control group. All graphs show mean values and error bars indicate
SEM. P-values were determined by one-way ANOVA and post-hoc Tukey HSD
analysis. The experiments depicted in (B) were performed by Matthias Zehner.
Despite their converse cytotoxic responses, both tested antigens showed similar hu-
moral responses. Surprisingly, a strong increase in IgG was detected in mice immunized
with the deglycosylated proteins, whereas IgG levels were only slightly elevated after the
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injection of untreated proteins. Noteworthy, all antibodies detected both the glycosy-
lated and deglycosylated isoform, implying that the fungal N-glycans do not contribute
to epitopes recognized by these antibodies. Both findings suggest that P. pastoris-
derived N-glycans do not improve MHC II-restricted presentation to CD4+ T cells.
Taken together, these in vivo data challenge the common conception that yeast-derived
N-glycans generally increase immunogenicity. The findings rather suggest that beneficial
effects on the cytotoxic response are antigen-dependent, and that fungal N-glycans even
bear the potential to decrease both cytotoxic and humoral responses in vivo.
4.8 Enforced N-glycosylation of non-glycoproteins can
affect MHC class I-restricted epitopes
One of the most important steps during T cell activation is the recognition of the MHC-
peptide complex on antigen presenting cells by the specific T cell receptor (TCR). The
binding of a peptide to the MHC binding groove is mainly mediated by MHC-specific
anchor residues [158, 159], and for MHC class I molecules critically depends on the inter-
action of the peptide C-terminus with the F-pocket in the binding groove [159]. Glycans
linked to anchor residues or any other residue facing towards the binding groove can pre-
vent the binding of peptides to MHC molecules [160, 161]. In addition, TCRs are highly
specific for their cognate MHC-peptide complex, and glycans on a certain epitope can
destroy the interaction that would normally occur between the TCR and the unglyco-
sylated epitope [160]. Since enforced N-glycosylation thereby holds the potential to de-
stroy MHC I-restricted epitopes, we finally wanted to elucidate whether N-glycosylation
of β-gal within a putative MHC I epitope is able to prevent cross-presentation. To
this end we investigated the cytotoxic response to β-gal96–103 (DAPIYTNV), another
H-2Kb-restricted β-gal epitope which can induce potent CD8+ T cell responses [162,
163]. It is important to note that the asparagine in this epitope is one of the putative
N-glycosylation sites in β-gal (N103, see Figure 4.2). Since N103 is the first N-glycan
acceptors in β-gal (Figure 4.2), and N-glycosylation preferentially occurs towards the N-
terminus [143], it is very likely that N103 is glycosylated after expression by P. pastoris.
We repeated the immunization experiment as depicted in Figure 4.18 B and investi-
gated the in vivo cytotoxicity against peptide-pulsed target cells after the immunization
of mice with the P. pastoris-derived β-gal as before. This time, however, we pulsed tar-
get cells with the (unglycosylated) β-gal96–103 peptide (DAPIYTNV). In contrast to the
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response to ICPMYARV, we did not observe any cytotoxicity against target cells that
were pulsed with the DAPIYTNV peptide (Figure 4.20 A). This result indicates that
CD8+ T cells in these mice were not primed against the (unglycosylated) β-gal96–103 pep-
tide (DAPIYTNV) after vaccination with the P. pastoris-derived β-gal. This, in turn,
could be explained by an N-glycan present on N103 in β-gal.
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Figure 4.20: Epitope-specific in vivo cytotoxicity of P. pastoris-derived β-gal
(A) Recipient mice (n ≥ 5) were vaccinated with β-gal (triangles) or left un-
treated (squares) as depicted in Figure 4.18 B. Injected target cells were either
pulsed with β-gal497–504 (ICPMYARV, left panel) or β-gal96–103 (DAPIYTNV,
right panel). The specific elimination of target cells was determined by flow
cytometry and % cytotoxicity was calculated. Bars show mean values, error
bars indicate SEM. P-values were determined by one-way ANOVA and post-
hoc Tukey HSD analysis. (B) Scheme of truncated β-gal(V10–H451). (C) His-
tagged proteins were purified by affinity chromatography from P. pastoris trans-
formed with β-gal(V10–H451) or vector backbone only (control). Pooled eluate
fractions were separated by SDS-PAGE and analyzed by coomassie staining,
western blot against the His-tag and far-western blot with MR-CTLD.
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To further investigate the glycosylation state of the asparagine N103, we transformed
P. pastoris with the deletion-mutant β-gal(V10–H451). This protein comprises the β-
gal96–103 epitope DAPIYTNV with the putative glycosylation site N103 but lacks the
remaining N-X-S/T motifs N461, N705 and N726 present in β-gal(V10–L731)(compare
Figure 4.20 B and Figure 4.2 B). This highly truncated protein was not efficiently se-
creted anymore and was hence purified by a one-step IMAC from yeast pellets. As a
purification control, yeast cells were transformed with vector backbone only. We were
able to purify a His-tagged protein from β-gal(V10–H451)-transformed yeast cells, which
was not present in control-transformed cells (Figure 4.20 C). Importantly, this purified
β-gal(V10–H451) still reacted with the MR-CTLD in a far-western blot (Figure 4.20 C),
just like β-gal(V10–L731) did before (Figure 4.5 E). Since N103 is the only N-glycan
acceptor site in the truncated β-gal(V10–H451), this reactivity indicates the presence of
a high-mannose glycan on N103, which in turn also argues for the glycosylation of N103
in the initially used β-gal(V10–L731).
Together, these results suggest that the N103 within the DAPIYTNV epitope is indeed
glycosylated in P. pastoris-derived β-gal, which prevents the cytotoxic activity against
(unglycosylated) β-gal96–103 (DAPIYTNV)-pulsed target cells, or in other words, destroys
the original DAPIYTNV epitope in β-gal.
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Due to their pivotal role in the initiation of an adaptive immune response, professional
antigen presenting cells (APCs) like dendritic cells (DCs) have become important targets
in vaccination approaches, and various strategies have been developed to deliver antigens
specifically towards DCs [164]. Among these strategies, fungal glycosylation was shown
to be a promising strategy to target C-type lectin receptors on DCs and increase the
immunogenicity of certain antigens [120–123, 165]. Yet, success of this strategy has so
far only been proved for proteins which are glycosylated in their native state, and the
immunostimulatory impact of fungal N-glycans has remained elusive. In the thesis we
have demonstrated that the yeast Pichia pastoris (P. pastoris) glycosylates proteins as
soon as they are secreted, even if they are not glycosylated in their native state. We
have established a method to transfer this strategy to proteins that lack intrinsic N-
glycosylation sites by the introduction of an engineered glycosylation motif and have
proved that the attached N-glycans are specifically recognized by the MR. However, our
data do not indicate an immunostimulatory effect of yeast-derived N-glycans per se and
suggest that the effect of such targeting strategies in vivo critically depend on the nature
of the antigen and potential immunodominant epitopes.
5.1 Enforced N-glycosylation by Pichia pastoris as a
tool to glycosylate non-glycoproteins
In comparison to the bacterial expression system E. coli, P. pastoris has been introduced
relatively recently [111]. Yet, it quickly gained popularity and is now broadly used in
industry and academia [108, 166–168]. One advantage that accounts for its increasing
application in protein production is the ability for post-translational modifications such
as disulfide bond formation and glycosylation [112]. These modifications contribute to
proper protein folding considerably and are important for protein functionality [169].
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N-glycosylation of characterized glycoproteins at their native glycosylation sites has
been repeatedly reported in P. pastoris [170–172]. Additionally, putative glycoproteins
that have been expressed for biochemical studies in P. pastoris show N-glycosylation at
predicted N-glycosylation sites [173, 174], though it is not known whether these sites
are also glycosylated in the native proteins. Taken together, this suggests that any N-
X-S/T sequon will be readily glycosylated by P. pastoris, as long as the protein enters
the secretory pathway.
Indeed, our data clearly show that recombinant β-gal(V10–L731), though not glyco-
sylated in its native state in E. coli, is N-glycosylated when expressed in P. pastoris,
as confirmed by glycosidase treatment and subsequent SDS-PAGE analysis in compari-
son to the E. coli-derived protein (Figure 4.5). These data are in line with the work of
Garc´ıa et al., who showed that α-amylase from Bacillus licheniformis gets N-glycosylated
after expression by P. pastoris [175], but seem to contradict a study on the human
prostaglandin H synthases 1 and 2 [176]. In the latter study, the two glycoproteins with
4 or 5 N-X-S/T sequons respectively have been expressed in P. pastoris. In each of the
native proteins, one of these motifs is not glycosylated. Interestingly, Kukk et al. showed
that the recombinant proteins from P. pastoris are glycosylated not at all potential but
only at the same sequons that are also occupied in the native proteins. On the other
hand, ovalbumin, which bears only one N-glycan attached to N292 in its native form
[72], is consistently glycosylated at both possible N-X-S/T motifs (N292, N311) after
recombinant expression in P. pastoris [120, 171]. Of note, during biosynthesis in the
hen oviduct, native ovalbumin occurs in the di-glycosylated form, too. However, this
di-glycosylated species exists only transitionally and is deglycoslyated by a site-specific
peptide:N-glycanase at position N311 before secretion [177]. This suggests that the mere
presence of N-X-S/T might not automatically be sufficient for efficient glycosylation by
P. pastoris. Instead, other factors like the presence of substrate-specific glycosidases or
sequon accessibility during protein folding (i.e. sterical hinderance) might influence site
occupancy and thereby the success of enforced N-glycosylation.
The recombinant β-gal(V10–L731) used in this thesis bears 4 putative N-glycosylation
sites (N103, N461, N705 and N726, Figure 4.2). N103 and N461 are both located within
less defined loop-like structures in the binding groove and play a role rather in substrate
binding than in structure determination [178]. N103 is more exposed to the surface,
whereas N461 is slightly buried within the protein’s core. N705 is located at a surface
loop structure within a beta-barrel and N726 is positioned on a linker peptide between
91
5 DISCUSSION
two beta-barrel domains. It has been suggested that protein folding into secondary do-
mains can progress too fast for the oligosaccharyltransferase to glycosylate a sequon,
simply by reducing the sequon’s spatial and temporal accessibility before it gets buried
within the protein [179]. Additionally, surface exposed sequons might not be glycosylated
when they engage in hydrogen bonds or are close to disulfide bridges [180]. Vice versa,
protein glycosylation at unintended sites could interfere with protein folding. Taking
this into account, it is likely that glycosylation of e.g. N461 favors misfolding and pro-
tein aggregation. Western blot analysis of yeast pellets and supernatants revealed that
pellets include protein isoforms which show a roughly 10 kDa higher apparent molecu-
lar weight (Mw) (Figure 4.3). The uncleaved signal sequence has a calculated Mw of
9.3 kDa and could account for the molecular weight shift. Nonetheless, the pellet signal
is also less sharp than the supernatant signal, suggesting that it might rather represent
additional glycoforms with several glycosylated sites or a hypermannosylated glycan.
These glycoforms are possibly not secreted due to protein misfolding or sterical issues
when passing through the translocon.
Standard high-mannose glycans with 8–12 mannose residues have a Mw of roughly
1.7–2.4 kDa. As the deglycosylation of the purified β-gal(V10–L731) resulted in a very
small electromobility shift (Figure 4.5 E), it seems plausible that only one or two as-
paragines are glycosylated in the secreted glycoform. The expression of the truncated β-
gal(V10–H451) suggests that N103 is glycosylated, because β-gal(V10–H451) only bears
this particular N-X-S/T motif but is still recognized by the MR (Figure 4.20 C). Fur-
ther studies with the recombinant β-gal(V10–L731) such as mass-spec analysis could
shed light on the site occupancy, thereby adding more information on the restrictions of
enforced N-glycosylation on intrinsic N-X-S/T sites as a glycosylation strategy. Addi-
tionally, as protein folding rates are influenced by culture and induction conditions, the
fine-tuning of these parameters might allow to adjust the ratio of distinct glycoforms to
a more or less glycosylated variant, thereby generating the optimal glycosylation-degree
needed for a certain purpose such as receptor targeting.
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5.2 Translating enforced N-glycosylation to
non-glycoproteins that lack intrinsic N-X-S/T motifs
Current subunit vaccines mainly focus on outer surface proteins of pathogens like viral
envelope proteins [110, 181, 182]. These antigens are of particular interest in terms
of humoral responses against extracellular pathogens. When it comes to intracellular
pathogens, where a cytotoxic response is needed, inner pathogenic proteins like viral core
proteins could represent additional targets. Unfortunately, many core proteins such as
those of certain HBV genotypes [183, 184] do not bear any intrinsic glycosylation motif at
all and would hence not be a substrate for the presented enforced glycosylation strategy.
To solve this problem, we introduced an engineered glycosylation site upstream of the
multiple cloning site in a yeast expression vector. Our proof of principle experiments
with GFP clearly show that the elaborate engineering of a glycosylation motif yields a
high percentage of glycosylated protein in P. pastoris (Figure 4.11). Interestingly, our
glycosylation tag also worked for HEK293T cells, though in these cells roughly half of
the protein was obtained in its unglycosylated form, which might be either a result of the
yeast-optimized amino acid sequence or the applied cell culture conditions (Figure 4.13
A).
The GFP fluorophor forms after protein folding by covalent linkage involving the
residues 65–67 [185]. Changes in GFP amino acid composition have led to the develop-
ment of enhanced GFP with changed fluorescent properties [149], and the introduction
of structural constraints like disulfide bonds even led to the discovery of redox sensitive
GFPs [186], which show altered fluorescence properties in their oxidized and reduced
states respectively. Hence, we would expect to dectect different fluorescent properties
if artificially introduced glycans would lead to misfolding or structural disturbance of
GFP. However, the comparison of fluorescence properties among our yeast-derived and
HEK-derived GFPs (Figure 4.14) shows identical properties throughout all GFP variants
irrespective of their glycosylation state. This suggests that placing an N-X-S/T motif
distant from structure determining residues could help to minimize the risk of glycan
interference with protein folding. Besides being beneficial for protein secretion, proper
folding might be an issue if enforced N-glycosylation is applied to proteins that should
retain their native conformation, e.g. for an enzyme replacement therapy.
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Engineered N-glycosylation sites have previously been applied by other groups in sev-
eral expression systems for quite different purposes such as topology studies of membrane
proteins [187], increasing the secretion of heterologous proteins [188], or rendering pro-
tein properties like their stability in terms of in vivo clearance [189]. We suggest that
engineered glycosylation sites are additionally useful to tag unglycosylated proteins with
certain glycans — determined by the expression host — in order to target receptors or
other proteins that bind to these certain glycans.
In addition to N-glycosylation, it has to be considered that O-glycosylation might
also occur during recombinant expression. Similar to the data on N-glycosylation, O-
glycosylation by P. pastoris has been reported for serine and threonine residues that are
not occupied in the native proteins [190, 191]. Additionally to a possible interference of
such O-glycans with the folding and the function of recombinant proteins, they might
also serve as additional ligands of certain lectins, and hence represent a targeting strategy
themselves. Nevertheless, there is no clear consensus sequence for O-glycosylation, and
attempts to introduce O-glycans accordingly rely on the fusion of larger protein subunits
or whole proteins that are known to be O-glycosylated in their native state [120, 123].
Hence, enforced N-glycosylation should be favored especially for small proteins, where
the fusion of large polypeptides can strongly influence the protein’s physicochemical
properties and functionality.
5.3 Targeting C-type lectin receptors by protein
expression in Pichia pastoris
In the early days of protein biochemistry, receptors were mainly discovered by the pu-
rification of homogenous protein solutions from cells that are responsible for a certain
binding or enzymatic activity. Following this forward approach, the mannose receptor
was first purified by Philip D. Stahl and coworkers when they tried to isolate the re-
ceptor on macrophages that mediates the binding to and the uptake of mannosylated
glycoproteins [192, 193]. Nowadays, modern genetic techniques prove that the simple
picture of one receptor mediating one activity is outdated. Certain receptors are evolu-
tionary or functionally related to each other and might show partially overlapping ligand
specificities [61, 194]. Such receptors might simply be redundant and serve as backup
systems. However, in the case of antigen presentation, the uptake of the same antigen
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by different receptors even leads to different processing pathways [51]. Additionally,
receptors like the MR bear multiple domains allowing the binding of not only one, but
several quite different substrates, which enables the receptor to fulfill diverse functions
[195]. Thus, modern targeting strategies have to handle different challenges regarding
target specificity. They have to discriminate between structurally related but function-
ally different receptors and to target those structures on the receptors that lead to the
desired downstream effects like certain signaling or trafficking events.
The uptake of P. pastoris-derived β-gal by HEK cells proved that the yeast-derived
glycans on the recombinant protein are indeed ligands of the MR (see Figure 4.6). These
findings are perfectly in line with the results of Lam et al., who demonstrated the uptake
of P. pastoris-derived OVA by MR expressing CHO cells [122]. Together, this not only
suggests that P. pastoris uses quite a restricted set of high-mannose glycans, regardless of
whether the glycosylation site is occupied in the native protein or not, but also that the
natural glycans of OVA and P. pastoris-derived glycans are structurally closely related.
This idea is further supported by a ligand analysis of purified human mannose receptor
performed by Ke´ry et al. in 1992 [70]. In this study, they show that the receptor
has a strong preference for branched mannosides with α-1,6- and α-1,3-linkages. These
linkages not only occur as free accessible branched trimannosides in the most prevalent
N-glycans found on OVA [72], but are also a core structure of all high-mannose glycans
in the α-1,6 branch [196] and hence potentially present in P. pastoris-derived glycans.
In contrast to HEK cells, BM-DCs are well equipped to capture a broad variety of
antigens by the expression of diverse endocytic receptors such as the MR [51], DEC205
[197, 198], Dectin-1 and Dectin-2 [199, 200], Fc receptors for IgG (FcγR) II and III [201]
or scavenger receptors [202] but also by constitutive macropinocytosis [203]. Hence,
it should be highlighted that the vast majority of the P. pastoris-dervied recombinant
antigens are taken up by the MR on these cells, as shown by the decreased uptake in
MR-deficient BM-DCs (see Figure 4.7). Beyond that, our data clearly show that yeast-
derived β-gal and NST-GFP are solely recognized by the C-type lectin part of the MR
but neither by its cysteine-rich domain nor the fibronectin II domain (see Figure 4.5
and Figure 4.11). Importantly, binding and uptake disappeared after deglycosylation
with PNGase F or Endo H, thus proving that our model antigens bound exclusively
via N-glycans to the MR. Since the MR was also shown to bind P. pastoris-derived O-
glycans [122, 123], this further suggests that neither β-gal nor NST-GFP bear excessive
O-glycans. Taken together, this implies that the interaction between P. pastoris-dervied
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N-glycosylated proteins and the MR closely resembles the interaction between the model
antigen ovalbumin and the MR. Concordantly, both antigens, β-gal and NST-GFP,
are internalized by BM-DCs into the same compartments as ovalbumin (see Figure 4.9
and Figure 4.12 C), which proves that the presented method shows a very accurate
MR specificity for the in vitro targeting of BM-DCs. Noteworthy, glycan-dependent
uptake could also be demonstrated for human peripheral blood mononuclear cell-derived
DCs and macrophages (Figure 4.15), suggesting that targeting strategies based on N-
glycosylation by P. pastoris might also be translated to humans.
Beside two recent studies that used novel plant lectin-based arrays to characterize
glycans on recombinant proteins from P. pastoris [123, 204], only two other mammalian
C-type lectins have been tested explicitly for the binding of P. pastoris-derived glycans,
namely DC-SIGN [122, 123] and the mannose-binding lectin (MBL) [123]. The mouse
genome encodes 8 different homologues of human DC-SIGN (SIGNR1-8), none of which
is a clear ortholog [205]. Of these, only SIGNR3 shows the same substrate specificity
as DC-SIGN for both high-mannose and fucose-terminated glycans [206]. SIGNR3 has
been shown to be expressed by some subtypes of DCs and other myeloid cells in vivo but
not by BM-DCs [200, 207]. MBL, on the other hand, is a soluble serum protein which is
secreted by the liver [208]. Both proteins are hence possible binding partners of enforced
N-glycosylated proteins in in vivo targeting strategies, or in the case of SIGNR3 also for
ex vivo targeting strategies of isolated primary cells.
Other C-type lectins that were described to bind mannose comprise Endo180 (uP-
ARAP) [209], langerin (CD207) [210], Dectin-2 [211], dendritic cell immunoreceptor
(DCIR) [212, 213], dendritic cell lectin (DLEC or BDCA-2) [212, 214], macrophage C-
type lectin (MCL) and macrophage-inducible C-type lectin (Mincle) [212] as well as the
collectin surfactant protein D (SP-D) [215]. The latter is structurally related to the
MBL but is mainly secreted by epithelia lining environment-exposed surfaces like the
lung, where it participates in innate immunity against inhaled microorganisms [216]. Of
the other C-type lectins Endo180 is structurally the closest relative of the MR and thus
a member of the MR family [209]. It is also expressed on macrophages and fibroblasts
[217]. Instead of antigen-uptake, however, the prominent function of this receptor seems
to be the turnover of the extracellular matrix, as it binds collagen via its MR-homolog
fibronectin II domain and directs it towards lysosomal degradation [218]. In this re-
spect, Endo180 has gained interest for its role in cancer progression and has recently
been identified as a target to treat bone cancer [219].
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Up to now, there is no data available on the interactions between P. pastoris-derived
glycans and C-type lectins other than the MR, DC-SIGN or MBL. Like the MR or
DC-SIGN many of the other membrane bound C-type lectin receptors were described to
play a role in antigen uptake und presentation [55, 58, 60, 220, 221]. Consistently, the
targeting of mannose-specific lectins by P. pastoris-derived proteins is widely considered
to be used as a vaccination strategy [116, 120–122, 222, 223]. However, some receptors
like Endo180 also play important roles in diseases, for example cancer [224]. Hence, it
will be interesting to identify interactions of P. pastoris-derived glycoproteins with other
putative targets to reveal both unwanted side effects of therapeutics and potential new
applications beyond antigen delivery.
5.4 Alternative targeting approaches for C-type lectins
in comparison to enforced N-glycosylation
DEC205 (CD205) and phospholipase A2 receptor, the two remaining members of the
MR family besides Endo180 and the MR, bear mutations in the CRD residues that coor-
dinate calcium and have therefore no predicted calcium-dependent carbohydrate binding
activity. Indeed, no C-type lectin activity has been documented for either DEC205 or
phospholipase A2 receptor so far. Instead, DEC205 was described to participate in the
uptake of ligands that are expressed during apoptosis and necrosis, thereby playing a
role in peripheral tolerance [225]. Additionally, DEC205 was reported to mediate the
binding and the uptake of class B CpG oligonucleotide, and it thus plays a key role in the
adjuvants effect of CpG by delivering it to TLR9 positive endosomes [226]. The phos-
pholipase A2 receptor on the other hand binds non-glycosylated ligands independently
of Ca2+ by protein-protein interaction via its CTLD5 [227–229].
These two members of the MR-family illustrate how enforced glycosylation with spe-
cific glycans might complement classical targeting strategies in the case of lectins. Clas-
sical approaches typically rely on the generation of monoclonal antibodies against the
target of interest, which are subsequently coupled to the cargo protein. A recent al-
ternative to antibodies are aptamers — small RNA molecules with a defined structure
that resulted from repeated selection cycles in a process termed systematic evolution of
ligands by exponential enrichment (SELEX) [230]. Both techniques have, for instance,
been used to target DEC205 [231–233]. However, aptamers require the generation and
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purification of the selective targeting agent (i.e. the aptamer), the purification of the
cargo protein and finally a coupling reaction to connect those two. Recombinant anti-
body technology allows at least to circumvent these additional steps by encoding the
fusion protein directly in the DNA. Enforced glycosylation follows the same recombinant
principle and combines all three steps in one purification, which might save costs and
time when it comes to large-scale production for therapeutic purposes. Another possible
pitfall of both antibody and aptamer approaches is inbuilt by the choice of the target
molecule that is used to raise the antibody or aptamer. If, for example, an aptamer or
antibody is raised against a CRD of a C-type lectin, it is likely that a positively selected
molecule binds to one of the conserved regions that determine the overall CRD fold.
There are only subtle changes in the amino acid composition that determine whether a
CRD coordinates calcium or not [234]. Hence, such approaches require a very careful
post-production negative selection, as the sole positive selection against the main target
cannot exclude off-target binding to structurally related receptors with different ligand
selectivity.
In approaches where the target is a substrate binding site within a broadly distributed
protein motif like the CRD fold, attaching a natural ligand to the cargo-protein could
help to decrease off-target binding, and hence be a valuable alternative. Indeed, such an
approach has been performed recently by fusing the chemokine (C motif) ligand (XCL1)
to a model antigen to target it’s receptor XCR1 [235]. However, the fusion of full-
length proteins shares also a possible drawback with antibody fusion. As in the case of
antibodies, larger protein ligands might critically change the physicochemical properties
by the additional protein mass. Moreover, antigen-fusion with a natural ligand that
is biologically active might introduce unwanted side-effects. In this respect, enforced
glycosylation could help to break down the problem to the smallest unit that is needed
to bind the target receptor. In the case of the MR, this is only a glycan with no need
for any proteinaceous component (see Figure 4.1). Gain in total molecular weight after
the enforced glycosylation of the cargo protein will be way smaller in comparison to a
fused antibody, as demonstrated in the case of β-gal and NST-GFP where glycosylation
added only about 5 kDa (see Figure 4.11 E and Figure 4.18 A).
In any case, all targeting strategies have advantages and disadvantages and should be
considered as alternatives for each other to find the optimal strategy for the intended
target.
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5.5 The role of high-mannose glycans as
pathogen-associated molecular patterns and their
immunostimulatory capacity
Recombinant proteins are often associated with safety concerns due to possible immuno-
genic side-effects related to their atypical glycosylation patterns [236]. In particular,
fungal proteins have repeatedly been associated with immunogenicity due to their po-
tential to target mannose-specific C-type lectin receptors of the immune system by their
high-mannose glycans [112, 117, 118]. However, though less abundant, high-mannose
glycans are also found on human cells [237, 238] and mannose residues are not limited
to high-mannose glycans but remain also present in mammalian hybrid glycans (see
Figure 2.5). Furthermore, mannose-specific C-type lectins such as the MR or Endo180
have been related to homeostasis [124, 218]. Accordingly, Gazi and Martinez-Pomares
have proposed that mannose is no classical ’danger signal’ [80], which in turn suggests
that mannosylated proteins are not immunogenic per se. Our data support the thesis of
Gazi and Martinez-Pomares, as they show that the P. pastoris-derived glycans on β-gal
did not lead to BM-DC maturation (see Figure 4.16). Moreover, BM-DC pre-incubation
with the glycoprotein had neither an influence on the MHC class II-restricted presenta-
tion of OVA, nor on the cross-presentation of OVA, nor on the MHC class I-restricted
presentation of endogenous peptides (see Figure 4.17). These findings are perfectly in
line with the work of Luong et al., who did not measure any IL-12 or TNF-α release by
BM-DCs upon incubation with P. pastoris-derived OVA [165].
Interestingly, the comparison of the relationship between C-type lectins across humans
and rodents revealed that lectins binding to endogenous ligands are more often conserved
than lectins involved in pathogen recognition [61]. Drickamer and Taylor suggested that
this could be explained from an evolutionary point of view, as each species encounters
unique pathogens, and hence pressure is much higher on the diversification of pathogen
recognition [61]. One example of such diversification is DC-SIGN with its 8 homolog
SIGN proteins encoded by mice genomes mentioned above [205]. Conversely, the MR
is highly conserved among both species, further supporting the idea that its basic role
might rather be homeostasis, and pathogen recognition would require additional ’danger
signals’. In line with this, the MR lacks any known signaling motif and seems to acquire
signaling capacity only by the interaction with other signaling competent receptors [80].
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This could also provide an explanation, why some studies report pro-inflammatory [78,
79] while others report anti-inflammatory responses upon MR ligation [77, 239].
As our experiments with MR-KO cells prove that the MR accounts for the main
uptake of enforced glycosylated β-gal and NST-GFP, it is no longer surprising that these
proteins do not influence DC-maturation. Instead, it seems likely that the discrepancies
to reported stimulatory effects of yeast-derived proteins in other studies are due to the
targeting of receptors other than the MR. Mincle and Dectin-2, for example, engage
immuno-receptor tyrosine-based activation motif (ITAM)-containing molecules like the
Fc receptor γ-chain (FcRγ) for inflammatory signaling [240, 241]. The targeting of
such receptors could happen if the chosen proteins simply bear other glycan structures
such as hypermannosylated N-glycans or O-glycosylation. Different glycosylation by P.
pastoris might be a result of either expression conditions or intrinsic protein properties
like potential glycosylation sites. For example, it was reported that hypermannosylation
is favored by the sequon NNTT [242]. But also mild induction conditions were suggested
to promote higher mannose amounts on the glycans, as the protein lasts longer in the
secretory pathway, which in turn increases the probability of further mannosyltransferase
activity [243]. Neither our model proteins nor our strong induction conditions with the
AOX1 promoter meet these criteria for hypermannosylation.
Besides unintended targeting of other receptors, it is even conceivable that one and the
same receptor is ligated in the different studies, but polyvalent or strong ligands such as
hypermannosylated proteins might promote a different receptor response in comparison
to the monovalent or weak ligands. Such a bimodal signaling triggered in the one or the
other direction by strong or weak ligation has been demonstrated by Pasquier et al. for
FcαRI via the ITAM-containing FcRγ [244].
In addition, it is possible that other signaling competent receptors may be activated by
contaminations with yeast-derived PAMPs that were co-purified. β-glucans, for example,
are main cell wall components of many yeasts [245], including P. pastoris [246, 247] and
target Dectin-1 [248, 249], which initiates secretion of inflammatory cytokines in vivo
[250]. Dectin-1 was also shown to trigger TNF-α release by BM-DCs in vitro upon
β-glucan binding to a level similar to LPS treatment [251]. We could not measure TNF-
α release after incubation with recombinant β-gal, suggesting no considerable β-glucan
contamination in our purified protein (see Figure 4.16 A).
Of course, though BM-DCs posses a huge set of PRRs, we cannot exclude that another
receptor that signals upon binding to P. pastoris-derived glycans is simply not expressed
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by these cells. However, nearly all in vivo studies use adjuvants like Freund’s complete
adjuvant (FCA) [222] or aluminium hydroxide [223] to boost immunostimulatory effects
of P. pastoris-derived vaccines, suggesting that the fungal glycans are not immunogenic
enough to serve as their own adjuvant.
5.6 The influence of Pichia pastoris-derived N-glycans
on the cellular and humoral response in vivo
Besides the potential to induce DC maturation, many C-type lectin receptors are known
as endocytic receptors that engage in antigen uptake leading to MHC-restricted pre-
sentation [197, 252–254]. Accordingly, several in vivo studies report increased CD8+
cytotoxic T cell and humoral responses when targeting C-type lectin receptors [53, 57,
221, 255–257] including mannose-specific lectins like DC-SIGN [258] or the MR [109,
259]. Due to their potential to target such receptors and the promising in vitro data on
increased immunogenicity after glycosylation by P. pastoris [120] Ahlen et al. intention-
ally used P. pastoris to express a highly mannosylated carrier protein bearing excessive
O-glycans to target C-type lectin receptors on DCs in vivo [121]. Additionally, several
studies used P. pastoris to produce subunit vaccines that elicit neutralizing antibod-
ies [222, 223] or both a humoral and a cellular response [116, 260]. However, none of
these studies investigated the sole effect of P. pastoris-derived N-glycans and hence the
contribution of N-glycans to improved cellular and humoral immune response in vivo
remained elusive.
To answer this question, we directly compared purified glycosylated versus enzymati-
cally deglycosylated proteins to circumvent the expression of the deglycosylated protein
in bacteria, as previously described [120]. Since β-gal from E. coli strongly activated DCs
(Figure 4.16), we chose the enzymatic approach to exclude interference of possible con-
taminants like LPS that would make it impossible to determine the effect of N-glycans
separately.
After the immunization of mice with glycosylated β-gal, we observed a CD8+ T cell
response that was decreased after deglycosylation as visualized by both cytotoxicity
and IFN-γ secretion (Figure 4.18 C, D). Since β-gal did not show a strong DC ac-
tivation in vitro irrespective of its glycosylation state (Figure 4.16 and Figure 4.17),
this suggests that the increased antigen uptake of glycosylated β-gal by APCs leads to
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an improved MHC I presentation in vivo. However, N-glycosylation had no beneficial
effect on NST-GFP-S8L-related cytotoxicity (Figure 4.18 E), though both NST-GFP
and β-gal showed a clear glycan and MR-dependent uptake by BM-DCs (Figure 4.7,
Figure 4.8 and Figure 4.12). Instead, NST-GFP-S8L-related cytotoxicity was even sig-
nificantly increased after deglycosylation, suggesting a negative influence of N-glycans
on the cross-presentation of this particular protein. The reason for this discrepancy
remains speculative. One explanation could be the presence of subtle O-glycosylations
that were not detected by our MR-CTLD blots. The amount of such glycans could differ
between both antigens and play only a decisive role as soon as the N-glycans are removed,
for example by engagement of other C-type lectins that contribute to MR-independent
binding or uptake in vivo.
In addition, differences in valency between β-gal and NST-GFP-S8L through different
numbers in N-glycans, O-glycans or both may lead to receptor-cross linking by one or
the other protein. Cross-linking can alter the trafficking of one and the same receptor
towards either recycling endosomes or lysosomes, as has been shown for Dectin-1 [261],
thereby favoring different presentation pathways. As receptor cross-linking is associated
with lysosomal targeting [262], this would imply that either β-gal is only cross-linked after
the removal of its N-glycans, which seems rather unlikely, or that the single N-glycan in
NST-GFP-S8L participates in cross-linking together with undetected O-glycans, which
is abrogated upon the removal of that N-glycan.
When we investigated the humoral response against the recombinant proteins, we
surprisingly observed a significantly higher response after the immunization with degly-
cosylated proteins in both cases (Figure 4.19). In particular, in the case of β-gal, there
was hardly any response measurable for the N-glycosylated protein at all. This suggests
that N-glycosylation has no beneficial influence on a humoral response in either case.
There are several possible explanations that might solely or in combination account for
this result. First, B-cells might get negatively selected if they express a BCR against
certain high-mannose N-glycans that also occur naturally in the bone marrow [237],
as BCR affinity against such glycans would cause auto-immunity. In accordance with
this, antibodies generated by vaccination with glycosylated NST-GFP-S8L recognized
their cognate antigens mainly independent of N-glycosylation (Figure 4.19 B). Second,
it has been shown that glycosylation is able to decrease protein susceptibility to pro-
teolytic degradation [263–265]. Such an inhibition could prevent efficient processing
of N-glycosylated antigens by lysosomal proteases, which would result in less MHC II-
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restricted presentation and hence a decreased humoral response. Third, OVA that is
internalized by the MR is predominantly processed for cross-presentation [51]. Uptake
by receptors like the MR could decrease the pool of pinocytosable antigens by captur-
ing glycosylated antigens and delivering them towards early endosomal compartments
related to cross-presentation. Lastly, it was shown that glycans within MHC II epitopes
can either prevent the binding of such epitopes to the MHC molecule or the recognition
of the MHC-peptide complex by the TCR [160]. β-gal with its 4 putative glycosylation
sites would be particularly susceptible to such an effect.
Of course, N-glycans could also block proteolytic processing, MHC I-binding or TCR
recognition during cross-presentation. Indeed, we found that the asparagine within the
MHC I-restricted β-gal epitope β-gal96–103 (DAPIYTNV) is likely to be N-glycsoylated
and that the unglycosylated DAPIYTNV peptide is not recognized by CD8+ cytotoxic
T cells after immunization with P. pastoris-derived β-gal (Figure 4.20). Importantly,
such blocking of MHC-restricted epitopes is not unique to enforced N-glycosylation, but
could potentially happen in any targeting strategy that uses covalent linkage of carrier-
molecules like antibodies, aptamers or glycans to the antigens, which is frequently done
by chemical cross-linking [59, 221, 233].
Two other critical points that will have impact on the overall immune response to P.
pastoris-derived N-glycosylated proteins are the choice of the adjuvant and the route of
vaccine delivery. As shown above, P. pastoris-derived glycans did not induce DC mat-
uration. Since DC maturation is a prerequisite for MR-dependent cross-presentation of
OVA [52], we used LPS as an adjuvant in vivo. Similarly, other groups used FCA [222]
or aluminium hydroxide [223] to boost immunogenicity in vivo. However, the choice of
the adjuvant formulation might strongly bias the immune response. Accordingly, adju-
vants targeting endosomal TLRs that are associated with the recognition of intracellular
pathogens (e.g. TLR3, TLR7/8 or TLR9) have been shown to act as strong activators
of CD8+ cytotoxic T cell responses [266] and might be better suited in combination with
MR-targeted vaccines.
The influence of the application route on the success of a vaccine might be explained
mainly by the presence of different DC subsets with differing receptor profiles [267]. In
comparison to intraperitoneal (i.p.) or intravenous (i.v.) virus administration, intra-
dermal (i.d.) and subcutaneous (s.c.) delivery were shown to predominantly induce
cytotoxic T-cell responses via cross-presentation, which suggests that DCs within these
tissues are suitable targets for vaccines aiming to induce cross-presentation [268]. How-
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ever, the cross-presentation of mannosylated synthetic long peptides (SLPs) proved to
be even more efficient after i.d. administration in comparison to s.c. [269], most likely
due to the different expression of the MR within these tissues [270]. Finally, the i.v.
injection of mannosylated proteins is not advisable due to clearance by liver sinusoidal
endothelial cells (LSECs) that also express the MR [87, 271].
5.7 Outlook and concluding remarks
We could demonstrate that P. pastoris is a valuable expression system to tag unglycosy-
lated proteins with glycans that are recognized by the C-type lectin part of the MR. Like
MR-internalized OVA, such modified proteins were readily delivered to early endosomal
compartments within BM-DCs that are associated with cross-presentation. As P. pas-
toris-derived high-mannose glycans bear the potential to target C-type lectin receptors
of the immune system, they are commonly considered immunostimulatory. However, we
could not observe that N-glycans in particular do expose any immunstimulatory capac-
ity per se. In addition, we showed that beneficial effects on the induction of a cytotoxic
CD8+ T cell response depend on the nature of the antigen and the epitope chosen for
MHC I-restricted presentation. This suggests that the influence of N-glycans on cytotox-
icity is hardly predictable and that each antigen subjected to enforced N-glycosylation
will have to be evaluated individually by experimentation. Beside the use of its glycans to
target C-type lectins and improve cytotoxicity, P. pastoris is generally considered to be
a potent expression system to generate high amounts of recombinant subunit vaccines.
Our data on humoral responses, however, suggest negative effects of N-glycosylation
on antibody production and strongly argue against the use of N-glycosylated proteins
expressed in P. pastoris for such purposes. Together, these findings have major im-
plications on the use of P. pastoris as an expression system for recombinant subunit
vaccines.
Beyond antigen presentation, endo- and phagocytosis by MR-family C-type lectin re-
ceptors also play a role in diverse other disease-related processes, including the entry of
intracellular pathogens like mycobacteria [272, 273], cancer progression [219], or lyso-
somal storage deseases [274]. In this respect, our presented enforced N-glycosylation
strategy with P. pastoris might even be exploited in addition to classical therapies to
block pathogen entrance, to prevent matrix turnover, or to restore lysosomal enzymes.
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Abbreviations
ABTS 2,2’-Azino-bis(3-ethylbenzothiazo-
line-6-sulfonic acid)
ANOVA analysis of variance
AP alkaline phosphatase
APC antigen presenting cell
APS ammonium persulfate
BCA bicinchoninic acid
BCR B cell receptor
BES N,N-Bis-(2-hydroxyethyl)-2-amino-
ethane sulphonic acid
BM-DC bone marrow-derived dendritic
cell
BSA bovine serum albumin
CD cluster of differentiation
CFSE carboxyfluorescein succinimidyl es-
ter
CHO chinese hamster ovary
CR cysteine-rich
CRD carbohydrate recognition domain
CTL cytotoxic T lymphocyte
CTLD C-type lectin-like domain
DAPI 4,6-diamidino-2-phenylindole
DC dendritic cell
DCIR dendritic cell immunoreceptor
DC-SIGN dendritic cell-specific ICAM-3
grabbing non-integrin
DLEC or BDCA-2 dendritic cell lectin
DMEC dermal microvascular endothelial
cell
DMEM Dulbecco’s Modified Eagle’s
medium
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
EEA1 early endosome antigen-1
ELISA enzyme-linked immunosorbent as-
say
Endo H Endoglycosidase H
ER endoplasmic reticulum
EtOH ethanol
FACS fluorescence-activated cell sorting
FCA Freund’s complete adjuvant
FCS fetal calf serum
FNII fibronectin II
β-gal β-galactosidase
GFP green fluorescent protein
GM-CSF granulocyte-macrophage
colony-stimulating factor
HBV hepatitis B virus
HEK human embryonic kidney
HEPES N-2-Hydroxyethyl piperazine-N’-
2-ethane sulphonic acid
HIV human immunodeficiency virus
HRP horseradish peroxidase
HSD honestly significant difference
i.d. intradermal
IFN-γ Interferon gamma
Ig immunoglobulin
IL-12 interleukin-12
IL-2 interleukin-2
IL-4 interleukin-4
IL-6 interleukin-6
IMAC immobilized metal affinity chro-
matography
IMDM Iscove’s Modified Dulbecco’s
medium
i.p. intraperitoneal
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Abbreviations
IRES internal ribosome entry site
ITAM immuno-receptor tyrosine-based
activation motif
i.v. intravenous
LAMP-1 lysosomal-associated membrane
protein 1
LN lymph node
LPS lipopolysaccharide
LSEC liver sinusoidal endothelial cell
MΦ macrophage
MACS magnetic-activated cell sorting
ManLAM mannose-capped lipoarabino-
mannan
MBL mannose-binding lectin
MCL macrophage C-type lectin
MCS multiple cloning site
M-CSF macrophage colony-stimulating
factor
MeOH methanol
MF mating factor alpha prepro leader se-
quence
MFI mean fluorescence intensity
MHC major histocompatibility complex
Mincle macrophage-inducible C-type
lectin
MOPS 3-(N-Morpholino) propane sul-
phonic acid
MR mannose receptor
Mw molecular weight
NCD non-communicable disease
Ni-NTA nickel-nitrilo-triacetic acid
OVA ovalbumin
OVA-647 Alexa Fluor 647-labeled ovalbu-
min
P. pastoris Pichia pastoris
PAMP pathogen-associated molecular
pattern
PBMC peripheral blood mononuclear cell
PBS Phosphate-buffered saline
PCR polymerase chain reaction
PFA paraformaldehyde
PMSF Phenylmethylsulfonyl fluoride
PNGase F Peptide-N-Glycosidase F
PRR pattern recognition receptor
RPMI Roswell Park Memorial Institute
RT room temperature
S8L SIINFEKL
s.c. subcutaneous
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate poly-
acrylamide gel electrophoresis
SELEX systematic evolution of ligands by
exponential enrichment
SEM standard error of the mean
SLP synthetic long peptide
SP-D surfactant protein D
TAE Tris-acetate-EDTA
TBS Tris buffered saline
TCR T cell receptor
TEMED N,N,N’,N’-Tetramethylethylene-
diamine
Th cell T helper cell
TLR toll-like receptor
TNF-α tumor necrosis factor alpha
Trf transferrin
Tris tris(hydroxymethyl)-aminomethane
Triton X-100 Polyethylene glycol alkyl-
phenyl ether
Tween 20 Polyoxyethylene-20-sorbitan
monolaurate
XCL1 chemokine (C motif) ligand
YNB yeast nitrogen base
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Glossary
DesTCR CD8+ T cells that recongnize three endogenous peptides in the Kb context
HEK-MR HEK cells expressing the MR
hNST-GFP NST-GFP expressed bei HEK293T cells
hQST-GFP QST-GFP expressed bei HEK293T cells
MR-CTLD Fc chimeric protein of MR CRDs 4–7 and the Fc part of human IgG1
MR-Nterm Fc chimeric protein of MR N-terminal part (CR, FNII, and CRDs 1–2)
and the Fc part of human IgG1
NST-GFP A GFP derivative with an N-terminal NST sequon
NST-GFP-S8L NST-GFP with a C-terminal S8L sequence
OT-I CD8+ T cells that recognize the ovalbumin peptide OVA257–264
OT-II CD4+ T cells that recognize the ovalbumin peptide OVA323–339
QST-GFP A GFP derivative with the N-terminal control sequence QST
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A Plasmid maps
All plasmid maps were generated with CloneManager 5 software (Sci-Ed).
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